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	Theoretical	Background	
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1.1	 Nanotechnology,	 Nanomedicine	 and	
Drug	Delivery		
Over the last decade the application of nanotechnology to medicine is 
completely reshaping our idea of therapy and diagnostic. It is common 
knowledge that standard therapeutic approaches may suffer from poor efficacy 
and several side effects. Cancer, for example, as a major cause of death needs 
new therapeutic approaches, which target the disease and avoid drug resistance. 
Nanomedicine, and in particular drug delivery systems (DDS), promise to 
address unmet medical needs in cancer and other diseases. This exciting 
interdisciplinary arena lies at the intersection of different research areas such as 
engineering, biotechnology, and material science [1]. Someone glimpses into 
nanomedicine the avenues for a sort of next industrial revolution, which will 
improve both the health and wealth of nations. Among the most impressive 
future trends I would mention personalized medicine, which has the ambition of 
tailoring health care to each person’s unique genetic makeup [2]. Also, another 
breakthrough that may change our perception of healthcare is the creation of 
point-of-care (POC), capable of bringing the laboratory diagnostic test outside of 
traditional care settings [3]. POC devices may be simple enough to be used at 
the primary care level and in remote settings with no laboratory infrastructure. 
These solutions potentially enable patients to self-test in the privacy of their 
homes.  
It must be pointed out, though, that the lack of scientific information on 
health risk and the challenges on translational research might postpone this 
“nanorevolution” [3, 4]. Whatever your view, nanotechnology is invading 
virtually every segment of industry. Mind how it is entering everybody’s home 
through mobile phones, computer and other high technology devices. It is 
thanks to advances in nanolithography, for example, that transistors get smaller 
and smaller and computer processors consequently faster [2]. Also, you may 
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likely find a nanotechnology-based product among your cosmetics. Skin creams 
and other lotions often contain nano sized parcels of ingredients (as in the case 
of liposomes) to improve the solubility of ingredients and add shimmer [5]. 
Moreover, a process frequently used for the formulation of cosmetics is 
nanoemulsion (NE), by which one liquid disperses in nanoscale droplets 
throughout the other. The derived fine texture allow for the transport of 
beneficial compounds deep into the skin and in high concentrations [6]. The list 
might go on and on ranging from energy to coating and paints and many other 
sectors. 
However, while the future is happening, how many average citizens could 
give a definition of nanoscience, nanobiotechnology, nanomedicine, 
nanocosmetics, nanomaterial, nanocarrier, nanoelectronics and so on? True is 
that there is still much confusion in defining the nano world as it usually happens 
with emerging technologies. The word nano comes from Greek and stands for 
dwarf. Thereby, nanoscience deals with the study of molecules and objects which 
can be measured in nanometers (billionths of meter or 10-9 m). The birth and 
development of nanotechnology is still unclear, although naïve applications of 
nanoscience can be traced to medieval glaziers. By a nanofabrication process 
they produced the gold nanodots, which were responsible for the color of the 
famous glass windows of ancient churches. As far as the modern origin of 
nanotechnology, it is easier to converge toward one name, the Nobel Prize 
Richard Feynman. During the most famous lecture he was giving at the annual 
meeting of the American Physics Society at Caltech in 1959, he pointed at the 
different problems that can affect the miniaturization process since “all things 
do not simply scale down in proportion”. At the nanoscale different laws apply, 
so we have to expect different things to happen. Gravity becomes much less 
relevant and things stick together by molecular van der Waals attractions. Also, 
Feynman was the first to introduce the concept of bottom-up approach to the 
fabrication of miniaturized device such as integrated circuits. To witness another 
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leap in nanotechnology we have to wait quite a few years. It is the 1981 when in 
the IBM labs they invent a new microscope capable to move a sharp tip so close 
to a conductive surface that the wave functions of the atoms of the surface and 
of the tips overlap. By applying a voltage electrons can “tunnel” the vacuum gap 
between the surface and the tip [7]. The Scanning Tunneling Microscope (STM) 
paved the way for another technique of scanning probe microscopy, namely the 
Atomic Force Microscopy (AFM), which is today very common for imaging, force 
measurement, and manipulation of matter at the nanoscale [8]. These powerful 
instruments for the investigation of the nanoscale are capable to resolve matter 
far beyond optical diffraction limit and both deserved a Nobel Prize. 
Therefore, we can define nanotechnology as the ability of manipulating and 
exploring matter on a nanometer scale length down to atomic dimensions. The 
nanoscale brings to materials and molecular assemblies different physical and 
chemical properties, thus introducing new features for therapeutic and 
diagnostic applications.  The lifelong concern of mankind for improving human 
health has eventually brought the new field of nanomedicine to blossom from 
the application of nanotechnology cues to medicine. This interdisciplinary 
research area has given a strong boost to the development of new diagnostic 
and therapeutic strategies trying to address the major issues of medicine [9]. 
Conventional anticancer therapies, for example, are known to be plagued by 
severe side effects and poor efficacy. The main reason behind these drawbacks 
is due to the lack of selectivity of therapeutic agents for the diseased tissues. 
Thereby, in spite of accumulating mostly at the target site, the drug interacts 
indiscriminately with the rest of the body killing also the healthy tissues and 
significantly decreasing the effective therapeutic dose. The need to maximize the 
biodistribution and pharmacokinetics of therapeutic agents has led to the 
development of nanosized DDS acting as reservoirs capable to protect the 
human body from the adverse effect of drugs and vice-versa [10]. During blood 
circulation, indeed, drugs encounter several barriers hindering their route to the 
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target site, such as the uptake from the reticuloendothelial system (RES). This 
network of phagocytic cells disseminated throughout the body plays a role in 
clearing the blood from unwanted foreign material. Thus, ideal DDS should be 
stable enough to allow for the accumulation of the encapsulated drug in the 
target tissue, while masking its payload from body clearance [11].  
Another constraint for an effective delivery strategy deals with the 
dimensions that DDS may possibly achieve. In fact size matters! From deep 
insight into tumor biology, leaky blood vessels and dysfunctional lymphatic 
drainage emerged as characteristic features consequence of rapid and defective 
angiogenesis. Unlike the free drug, which may diffuse non-specifically, 
nanocarriers with a size of about 100 nm can extravasate into the tumor tissues 
escaping through the fenestration of the defective vessels. Then, thanks to the 
dysfunctional lymphatic drainage it is retained close to the tumor cells where it 
can release the drug (for a schematic representation see Figure 1.1) resulting in 
the so called permeability and retention effect (EPR) [12]. One can take 
advantage of this pathophysiological cue of tumors for the rational design of 
DDS which can passively accumulate at the diseased tissue. This is only one 
representative example of how medicine and nanotechnology met half way to 
foster new strategies for improving therapies. Designing nanocarriers with the 
right size is just the first requirement to potentially translate the DDS into the 
clinics. Then, several other properties of the nanocarriers can be modified to 
positively affect their therapeutic efficacy. These include biocompatibility and 
biodegradability, drug release mechanism and biodistribution. 
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Figure	 1.1	 Targeting	 of	 nanomedicines	 by	 the	 enhanced	 permeability	 and	 retention	 (EPR)	 effect.	
Notes:	 Differences	 between	 normal	 (A)	 and	 tumor	 (B)	 vessels	 are	 depicted.	 Tumor	 vessels	 contain	
large	 fenestrations	 between	 the	 endothelial	 cells:	 this	 structural	 characteristic	 allows	 the	
nanoparticles	 (NPs)	 to	 reach	 the	matrix	 and	 the	 tumor	 cells	 by	 the	 EPR	 effect.	 Conversely,	 normal	
tissue	 contains	 tightly	 joined	 endothelial	 cells:	 this	 prevents	 the	 diffusion	of	NPs	 outside	 the	blood	
vessels.	(Figure	redrawn	after	ref	[13]).	
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1.2	Aim	of	the	work	and	thesis	outline	
Conventional therapeutic approaches are plagued by some major limitations 
which nanomedicine promises to address combining the advances in medicine 
and biology with nanotechnology based drug delivery systems. Novel 
nanocarriers are being developed to sidestep fundamental problems of 
traditional drugs based on their ability to overcome poor water solubility issues, 
improve physical/chemical stability, enhance bioavailability and alter 
unacceptable toxicity profiles. In particular, the Holy Grail of any drug delivery 
system is to transport the required dose of a particular active agent to a specific 
disease or tissue site throughout the body and release it in a controlled fashion. 
This strategy should ultimately lead to minimizing toxic side effects and 
optimizing therapeutic benefit. Nevertheless, the application of engineered 
nanodrugs into the clinics still proves challenging due to some bottlenecks, 
especially at the translational level.  
Trying to give our own piece of contribution to this area of research, here we 
devoted the efforts toward the formulation of multifunctional drug delivery 
systems based on highly controllable liquid nanocapsules (NCs). We particularly 
drew the focus on the development of a robust and scalable technique to 
produce oil-core multilayer nanocarriers capable to encapsulate lipophilic agents 
of interest for nanomedicine. This methodology was a reliable platform for the 
implementation of further functionalities of great importance for drug delivery 
such as stimuli-responsive drug release mechanisms. 
In Chapter 2 we present an extensive work on the optimization of both the 
NE process and the layer-by-layer (LbL) deposition of naturally derived 
polymers at the liquid-liquid interface. This consolidated approach allowed for 
the preparation of versatile and highly controlled NCs with reproducible 
dimensional features (size ≈ 100 nm; PDI < 0.1). Thanks to their oil-core these 
NCs can pre-load several hydrophobic drugs overcoming tedious post-
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processing procedures. We proved our method to be flexible also employing 
different materials for NCs preparation. 
Moving from the results reported in Chapter 3, we upgraded the presented 
NCs to enhance their physical stability and to allow for spatially controlled 
release of chemotherapeutic agents. To achieve a stimuli-responsive release we 
chose an endogenous trigger which is characteristic of the nature of tumors 
microenvironment itself. The NCs were, indeed, finely engineered to be 
sensitive to the activity of particular enzymes overexpressed by several tumors. 
Finally, in Chapter 4 we present an early study on the integration of 
graphene oxide (GO) into NCs for drug delivery and bioimaging applications. 
As a derived form of graphene, GO exhibits many appealing and non-
conventional features that might be of huge impact for nanomedicine.  
  
 
 
 13 
1.3	References	
[1] V. Wagner, A. Dullaart, A.-K. Bock, A. Zweck, The emerging nanomedicine 
landscape, Nat Biotech 24(10) (2006) 1211-1217. 
[2] U. Food, D. Administration, Paving the way for personalized medicine: 
FDA’s role in a new era of medical product development, Silver Spring, MD: 
US Food and Drug Administration  (2013). 
[3] A. Larsson, R. Greig-Pylypczuk, A. Huisman, The state of point-of-care 
testing: a european perspective, Upsala Journal of Medical Sciences 120(1) 
(2015) 1-10. 
[4] M. Kendall, I. Lynch, Long-term monitoring for nanomedicine implants and 
drugs, Nature nanotechnology 11(3) (2016) 206-10. 
[5] M. Anis, G. AlTaher, W. Sarhan, M. Elsemary, Cosmetic Applications, 
Nanovate, Springer2017, pp. 243-260. 
[6] M.N. Yukuyama, D.D.M. Ghisleni, T.J.A. Pinto, N.A. Bou-Chacra, 
Nanoemulsion: process selection and application in cosmetics – a review, 
International Journal of Cosmetic Science 38(1) (2016) 13-24. 
[7] G. Binnig, H. Rohrer, Scanning tunneling microscopy—from birth to 
adolescence, reviews of modern physics 59(3) (1987) 615. 
[8] G. Binnig, C.F. Quate, C. Gerber, Atomic force microscope, Physical review 
letters 56(9) (1986) 930. 
[9] B. Müller, M.H. Van de Voorde, M. Van de Voorde, Benefit from 
Nanoscience and Nanotechnology: Benefitting Patients, Nanoscience and 
Nanotechnology for Human Health  (2017) 379-382. 
[10] R. Zeineldin, J. Syoufjy, Cancer Nanotechnology: Opportunities for 
Prevention, Diagnosis, and Therapy, in: R. Zeineldin (Ed.), Cancer 
Nanotechnology: Methods and Protocols, Springer New York, New York, NY, 
2017, pp. 3-12. 
[11] S. Manoochehri, B. Darvishi, G. Kamalinia, M. Amini, M. Fallah, S.N. 
Ostad, F. Atyabi, R. Dinarvand, Surface modification of PLGA nanoparticles 
via human serum albumin conjugation for controlled delivery of docetaxel, 
Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 
21(1) (2013) 58. 
[12] Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics 
in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins 
and the antitumor agent smancs, Cancer research 46(12 Pt 1) (1986) 6387-92. 
[13] G. Bozzuto, A. Molinari, Liposomes as nanomedical devices, International 
journal of nanomedicine 10 (2015) 975-99. 				
 14 
		 	
 15 
Chapter	2		
Ultrastable	Polyelectrolyte	Multilayer	Lipid	
nanocapsules	
	
	
Figure	2.1	Scheme	of	the	multilayer	deposition	on	pre-loaded	ultra-stable	liquid	template	by	means	of	
sonication	in	a	water	bath	of	the	two	phases	–	polymer	solution	and	suspension,	which	are	injected	
dropwise. 
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Abstract	
Liquid-liquid interfaces possess unique properties such as high interfacial 
tension and fluidity, which provide enhanced mobility for the achievement of an 
equilibrium assembly. Therefore, they are ideal templates for the preparation of 
polyelectrolyte multilayer nanocapsules. Drug delivery would particularly benefit 
from biodegradable polymer nanocapsules since they combine tunable shell 
properties with a liquid oily core capable to encapsulate high amounts of 
lipophilic payloads. However, governing the self-assembly of polyelectrolytes at 
the interface between to immiscible liquids can prove challenging due to the 
intrinsic instability and high reactivity of these systems. Here we report on the 
development of a robust platform for the preparation of ultrastable oil-core 
multilayer nanocapsules based on the optimization of both the nanoemulsion 
process and the Layer-by-Layer deposition technique. Our nanocapsules exhibit 
highly controlled dimensional features as highlighted by advanced 
morphological characterization. Moreover, they may be assembled with several 
naturally derived polymers and encapsulate a number of hydrophobic molecules 
thus showing multi-compartment and multifunctional features. These results 
together with their biocompatible nature may enrich their area of application in 
drug delivery, as well as in other bio-nanotechnology fields. 
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2.1	Introduction	
Finely controlled biodegradable nanocapsules (NCs) are today highly 
demanded for several applications such as drug delivery, cosmetic, food and 
agriculture [1-5]. The main benefits coming from the encapsulation of actives 
are for protection of the entrapped substances from adverse environment, for 
controlled release, and for precision targeting. All these features make NCs 
particularly desirable as drug delivery systems capable of positively altering both 
the farmacokinetics and the biodistribution of the drugs.  
Moreover, today a bunch of new candidate molecules emerging from drug 
discovery show poor water solubility, which represents an additional constraint 
to the delivery of these actives throughout the body [6]. Again, nanotechnology-
based formulations seem to be a smart answer to the improvement of drugs 
therapeutic performance thanks to the solubility enhancement they can provide 
through the core/shell architecture of nanocapsular systems. In fact, by masking 
hydrophobic drugs within a nanocavity with a hydrophilic external interface, one 
can dramatically improve the blood solubility of a wide range of therapeutics 
such as hydrophobic molecules, peptides, and oligonucleotides [7, 8]. This 
means in turn, enhancing drug bioavailability, lowering the required dose and 
thus reducing toxicity; all these effects thereby improve drug efficacy, safety and 
patient compliance.  
Moreover, by finely engineering the NC shell architecture, one can add many 
other desirable features for a drug delivery system such as an on demand release 
of the payload and an ability to target a specific site. 
Typical examples of delivery systems designed to improve the therapeutic 
index of poor water-soluble agents include liposomes, polymeric nanoparticles, 
solid lipid nanoparticles, and nanostructured lipid carriers.  
There are several available strategies to produce biodegradable NCs such as 
nanoprecipitation, emulsion diffusion, coacervation [9, 10], co-crystallization 
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[11], formation of complexes such as cyclodextrins [12], and use of aqueous 
mixtures with an organic solvent [13].  
However, all these approaches share some major limitations including safety 
issues and procedures leading to simple architectures that prevent a fine control 
and tuning of the shell properties [14]. Hence, combining degradable NCs along 
with a multifunctional and multicompartment architecture still remains 
challenging [15, 16].  
In this context, lipid NCs based on oil in water (O/W) NE technology 
provide an avenue to address some major issues. Firstly, these drug nanocarrier 
systems appear to be way more biocompatible than their polymeric 
counterparts, which may contain residuals from cytotoxic monomers, catalysts 
and organic solvents. Moreover, even when compared to liposomes - which 
despite many others encapsulating systems are already used in some cancer 
therapies - lipid NCs apparently have an edge over them. Otherwise than 
liposomes, indeed, lipid NCs have a high lipophilic drug loading capacity, do not 
require the use of organic solvents and they do not suffer from a premature 
release of their payload [17].  
True is that in order to achieve long term stability and use of (O/W) NEs as 
liquid templates for multilayer NCs, it is crucial to finely control both their size 
and polydispersity. In fact, these two features directly reflect on the NE shelf 
life.  
From a thermodynamic point of view (O/W) NEs may be seen as liquid-
liquid interfaces, which are highly dynamic and intrinsically unstable systems 
[18]. Basically, this is due to the immiscible nature of the oil and water phases 
and to the high interfacial tension, even when stabilized by surfactants. 
However, if one is able to take advantage of their elevated fluidity and tendency 
to reduce surface tension by interacting with adjacent molecules or 
nanoparticles, then it is possible to drive the assembly process in a unique 
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fashion [19]. Hence, (O/W) NEs show great potential as viable templates for 
ordered assembly of molecules and nanoparticles. 
Some attempts have been already pursued in this direction by carrying the 
process of multiple polymer deposition at liquid-liquid interfaces based on O/W 
NEs but with little control over size and stability. This is especially relevant 
when multiple polymer depositions are required, as it is in the case of Layer-by-
layer (LbL) multifunctional polymeric NCs [20-24]. 
LbL technique is recognized as one of the most promising methods to 
prepare engineered multifunctional NCs. It is based on the progressive 
deposition of polymer layers on a given template and it allows for control 
almost at the molecular scale [25-28]. The main driving force of the process is 
the electrostatic attraction between polyelectrolyte layers of opposite charge, 
which makes the deposition procedure relatively simple and straightforward 
[29]. However, in a typical protocol to obtain multilayer hollow capsules, the 
deposition of the polyelectrolyte-based shell is performed around a solid 
template, which eventually needs to be removed in order to leave an inner cavity 
acting as a reservoir. Due to the harsh conditions required for removing the 
template, several polymer layers are generally needed in order to strengthen the 
capsule and avoid damages. In addition, the large number of layers generally 
implies centrifugation and rinse steps, which in turn force to the use of dense 
templates hard to leach out [30]. For all these reasons, monodisperse hollow 
capsules are typically reported only in the case of sizes much larger than 200 nm 
or by use of strong synthetic polymers such as poly(allylamine hydrochloride) 
and poly(styrene sulfonate) [30]. Both conditions virtually dismiss the as 
prepared LbL capsules from an effective application as drug delivery systems 
[26, 31]. It is in this context that liquid templates sweep in as a viable way to 
overcome most of the limitations related to LbL around solid templates [31, 32]. 
Once the deposition of polyelectrolytes has been performed around a liquid 
drop it does not need to be removed, thus avoiding tedious and time consuming 
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post-processing and any constraint on the minimum number of layers [14]. 
Also, when using (O/W) NEs as liquid templates one can preload big amounts 
of lipophilic molecules – which are the most recurrent among therapeutic agents 
– by directly dissolving them into the oil phase [33-35].  
From a safety point of view, the oil-core itself should not represent an issue 
in principle. Whereas, all the risks of template residues and damaging of the 
polymer shell due to harsh leaching out conditions should be wiped out by the 
use of liquid templates [14, 36]. 
In this panorama, optimized (O/W) NEs capable to sustain multiple LbL 
depositions of biodegradable polymers may provide an effective avenue for the 
delivery of lipophilic agents. This way, on the one hand, one can take advantage 
of the classical LbL technique, which has emerged as one of the easiest and 
most controlled methods to deposit ultrathin polymer layers [25]; on the other 
hand, (O/W) NEs provide a lipophilic liquid core which allows for high 
payloads of powerful lipophilic drugs [23, 28], sizes under 200 nm and naturally 
derived polymer shells.  
Following this aim, we here report on the use of a liquid–liquid interface 
based on a O/W chitosan coated NE as a reliable template for multiple 
interfacial depositions of polymers to produce highly controllable polymer NCs 
[37]. Many efforts were devoted to redeem the limitations of the liquid core of 
LbL NCs in order to take advantage of their great potential as delivery systems. 
Through the development of new methodologies we produced ultrastable, 
highly concentrated (ca. 10 wt% oil phase), narrowly distributed NCs. Their 
morphological characteristics were highlighted by classical dynamic light 
scattering (DLS) combined with advanced analysis such as cryo transmission 
electron microscopy (cryo-TEM) and super resolution confocal microscopy 
(STED). Also, in order to assess the protection role of the polymer shell, we 
carried out biological tests comparing cell viability after incubation with NCs 
prepared with different number of layers around the liquid core. 
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Figure	 2.1.1	 (A)	 Schematic	 of	 the	 film	 deposition	 process	 using	 slides	 and	 beakers.	 Steps	 1	 and	 3	
represent	the	adsorption	of	a	polyanion	and	polycation,	respectively,	and	steps	2	and	4	are	washing	
steps.	 The	 four	 steps	 are	 the	basic	 buildup	 sequence	 for	 the	 simplest	 film	architecture,	 (A/B)n.	 The	
construction	 of	 more	 complex	 film	 architectures	 requires	 only	 additional	 beakers	 and	 a	 different	
deposition	sequence.	(B)	Simplified	molecular	picture	of	the	first	two	adsorption	steps,	depicting	film	
deposition	 starting	 with	 a	 positively	 charged	 substrate.	 Counterions	 are	 omitted	 for	 clarity.	 The	
polyion	 conformation	 and	 layer	 interpenetration	 are	 an	 idealization	 of	 the	 surface	 charge	 reversal	
with	each	adsorption	step.	(Figure	redrawn	after	ref.	[29]).	
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2.2	Results	and	Discussion	
Nanoemulsions	are	reliable	liquid	templates	
The opportunity to use O/W NEs as reliable liquid templates for the 
preparation of polyelectrolytes multilayer NCs strongly depends on NE stability 
and dimensional features, such as average size and size distribution. However, 
NEs are thermodynamically unstable systems due to the immiscibility of the oil 
and water phases, even when stabilized by surfactants. At the same time, it is 
behind their intrinsic dynamic and unstable nature that their unique behavior 
hides. The elevated interfacial tension and fluidity, indeed, provide high mobility 
for the achievement of an equilibrium assembly [19], making NEs viable 
templates for Layer by Layer polymer NCs. 
Moreover, the use of O/W NE based liquid templates allow for pre-loading 
of high amounts of lipophilic agents redeeming the subsequent built up of the 
polymer nanocapsule from a number of heavy constraints.  
Hence, by addressing the stability and dimensional issues, one can benefit of 
all the unique properties of O/W NE as liquid templates for multilayer NCs. 
In this work the typical limitations of liquid templates have been bypassed 
starting from nanomulsions stabilized by means of a polymer coating, namely 
secondary NEs, combined with an optimal re-dispersion process already 
described in a previous work [38].  
Small sizes (under 200 nm) and low PDI of the oil template (<0.1) were 
achieved through high-pressure homogenization according to a procedure 
previously reported [38]. For what concerns the template size, we used two 
different formulations, namely L130 and L90 (based on different concentrations of 
surfactant in oil 2.4 g/20 g and 4.8 g/20 g, respectively). These primary NEs 
feature a reproducible size, ranging from around 130 nm (L130) to around 90 nm 
(L90). Then, we stabilized the primary nanomulsions through a polyelectrolyte 
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coating made of chitosan (CT), a biodegradable polysaccharide [39]. To prevent 
aggregation, the secondary NEs were properly re-dispersed according to the 
procedure previously reported [38]. We were therefore able to highly improve 
monodispersion along with the stability of the liquid templates, as schematically 
represented in the case of L90 secondary NE in Figure 2.2.1b.  
 	
	
Figure	 2.2.1	 (a)	 cryo-TEM	 analysis	 of	 a	 double	 re-dispersed	 secondary	 NE	 sample	 after	 about	 six	
months	from	the	preparation;	(scale	bar:	200	nm).	(b)	Size	and	PDI	over	time	of	double	re-dispersed	
L90	based	secondary	NE	at	an	oil	concentration	of	10	wt%	(light	blue).	Comparison	at	0	time	among	
size	and	PDI	values	of	double	re-dispersed	(light	blue),	single	re-dispersed	(medium	blue)	and	non	re-
dispersed	(dark	blue)	L90	based	secondary	NE.		
As it emerges from the histograms in Figure 2.2.1b, performing twice the re-
dispersion process after coating the NE with chitosan avoided aggregation, and 
kept secondary NE size similar to the starting size of the primary NEs when 
compared to non-re-dispersed and single re-dispersed systems. More 
interestingly, this procedure guaranteed more than one year of stability. The 
DLS measurements performed in order to monitor the size and PDI changes 
over time, were also supported by morphological analysis. 
Still in Figure 2.2.1a we also reported the cryo-TEM of the double re-
dispersed secondary NE after about six months of preparation, which seems to 
confirm the DLS data. 
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Further investigations about the dimensional features of our secondary NEs 
were performed by super resolution fluorescence microscopy. In particular, L130 
and L90 secondary NEs (0.1 wt% polymer - 10 wt% oil) were analyzed using a 
confocal laser scanning microscope in stimulated emission depletion (STED) 
modality, because of their expected small size (Figure 2.2.2a,c).  
For this purpose, chitosan was chemically labeled with Fluorescein 5(6)-
isothiocyanate (FITC) before deposition. The results depicted in Figure 2.2.2 
seem in good agreement with the analysis carried out by DLS. 	 			
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Figure	 2.2.2	 STED	 analysis	 of	 L130	 and	 L90	 secondary	 NEs	 and	 the	 corresponding	 line	 profile	 of	 the	
intensities	comprised	between	the	two	arrows	shown	in	(a),	(c)	respectively.	The	red	dots	depicted	in	
panel	 b	 and	 d	 show	 the	 intensities	 of	 the	 corresponding	 pixel	 values	 in	 the	 image,	 red	 line	 is	 a	
Lorentian	fit	of	the	values.	(Scale	bar:	1	µm).	
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Multilayer	deposition	on	oil-core	nanocapsules	
The LbL technique has emerged as one of the most promising method to 
prepare engineered multifunctional NCs through the self-assembly of 
polyelectrolytes mainly driven by electrostatic interactions [25]. It is recognized 
as an easy and controlled technique to deposit ultrathin polymer layers around 
almost any kind of template. Nevertheless, only few attempts have been pursued 
to produce polyelectrolyte multilayer NCs starting from O/W NE based liquid 
templates [20-24]. As it was already discussed in the introduction to this chapter, 
this is also due to high reactivity of liquid-liquid interfaces, which can make the 
LbL deposition process difficult to handle.  
However, thanks to the stabilization of the primary NE described in the 
previous paragraph and to a customized wash-less deposition method, we 
managed to finely perform LbL technique around nanosized liquid templates. In 
particular, we obtained narrowly distributed oil-core multilayer NCs starting 
from a 20% O/W NE. We were able to deposit up to seven polymer layers 
while keeping the size below 200 nm and the PDI below 0.1. In order to 
preserve these dimensional features during deposition of several polymer layers 
onto highly concentrated secondary NEs (10 wt%), the LbL process was aided 
by a sonication step in a water bath at controlled temperature. In addition, to 
keep a good control on the mixing step, polymer solution, and NE template 
were injected and mixed drop wise. A scheme of this set-up is depicted in 
Figure 2.1. Finally, we identified by saturation method the optimal polymer 
amount to deposit at each step of the LbL procedure as reported in Figure S1 
in the Supplementary Information section. 
The results of these depositions are summarized in Figure 2.2.3 and 2.2.4 
(see also Figure S2 in the Supporting Information). The cryo-TEM analysis 
clearly shows the different size between the L90 based pentalayer (Figure 2.2.3a) 
and L130 based eptalayer (Figure 2.2.3d) confirming the size distribution 
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observed by DLS. Moreover, both the penta- and the eptalayer NCs, imaged in 
their frozen hydrated state, appeared to be formed by a dense core, 
corresponding to the oil template, surrounded by a well-defined electron-dense 
boundary. 		
	
Figure	2.2.3	(a),	(d),	Cryo-TEM	projection	images	of	L90	based	pentalayer	and	L130	based	eptalayer	NCs,	
respectively.	Panels	 (b)	and	 (e)	are	an	overlay	of	a	STED	acquisition	of	 the	FITC-chitosan	 (last	 layer,	
green),	and	a	confocal	acquisition	of	TRITC-chitosan	(underlying	layer,	red).	Panels	(c)	and	(f)	are	the	
line	profiles	of	the	FITC	fluorescence	intensities	comprised	between	the	two	arrows	shown	in	(b)	and	
(e),	respectively.	Red	dots	show	the	intensities	of	the	corresponding	pixel	values	in	(b)	and	(e),	while	
red	line	is	a	Gaussian	fit	of	the	values.	
We also characterized the size and distribution of our multilayer NCs, by 
STED analysis of both the L90 based pentalayer (Figure 2.2.3b) and L130 based 
eptalayer (Figure 2.2.3e). To this purpose, we labeled the last chitosan layer 
with FITC, while the second to last chitosan layer was stained with Rhodamine 
B isothiocyanate (TRITC) fluorophore to analyze the co-localization between 
them. In agreement with the DLS measurements, we proved by STED the 
narrow distribution feature of the developed NCs on both sizes (Figure 
2.2.3b,c,e,f); while the perfect matching between green and red colors (FITC 
and TRITC respectively) proves the effectiveness of the deposition 
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homogeneity. This analysis is a further evidence of the effective LbL deposition 
of each layer since only the last one was labeled with FITC.  
We then proved the loading capability of the NCs to be effective by 
dissolving inside the oily templates lipophilic model drugs like Nile Red (Figure 
2.2.4e) and curcumin, (Figure 2.2.4f), without affecting NCs size, PDI and 
templating capability.  
Another appealing feature of our liquid templates is their capability to 
undergo a multilayer deposition even after storing the secondary NE for more 
than one year. Such stability is reported in Figure 2.2.4f that depicts the LbL 
process in terms of size, PDI and Z-potential of a pentalayer prepared on a L90 
template loaded with curcumin stored for 14 months.  
In this study, we also showed the versatility of the method by testing other 
couples of polyelectrolytes (i.e. chitosan-sodium alginate, chitosan-hyaluronic 
acid) and the results of size, PDI and Z-potential are summarized in Figure 
2.2.4c, 2.2.4d and Table S2c, S2d in the Supplementary section.  
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Figure	 2.2.4	 Overlay	 of	 size	 increase	 and	 potential	 reversal,	 by	 DLS,	 showing	 the	 versatility	 of	 the	
deposition	process	in	terms	of	fluorophores	labeling	(a),	(b)	variety	of	biocompatible	polyelectrolytes	
(c),	 (d),	 loading	 capability	 of	 model	 drugs	 (e)	 and	 possibility	 to	 perform	 LbL	 deposition	 using	 14	
months	old	templates	(f).	
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Nanocapsules	number	of	layers	affects	their	biological	
applications		
To understand how the number of layers can affect the final biological 
application of our NCs we carried out a biological analysis testing L90 based 
systems. In particular, we compared a monolayer, a trilayer, and a pentalayer in 
order to keep the same chemical interface corresponding to chitosan in all the 
three cases. The starting NE was loaded with curcumin, which is hydrophobic 
as most of the nutraceuticals and has already demonstrated anticancer effects 
[40]. The three nanocapsular systems were put in contact with human colon 
cancer cell line (HT29) for 72 h; the results of the viability tests are shown in 
Figure 2.2.5a. The monolayer resulted more toxic than the trilayer and even 
more than the pentalayer at all times and concentrations tested. In particular, at 
the maximum concentration of curcumin (30 µg/ml), the monolayer reached 
the IC50 in 24 h, while the trilayer did it in 48–72 h and the pentalayer in 72 h. 
The time point at 72 h was sufficient for the monolayer to reduce the viability to 
very low values (almost 10%). In order to exclude that the difference of toxicity 
could be due to a different amount of internalized nanoparticles, we also carried 
out an internalization test of the three systems in the first 24 h, which showed 
no significant difference (Figure 2.2.5b). As expected, from this study it is clear 
that the number of layers has an impact on the final biological application 
confirming the protective function of the multilayer, especially when switching 
from the monolayer to the trilayer system. This feature is less pronounced when 
passing from the trilayer to the pentalayer. In addition to this consideration, it is 
valuable to remark the capability of a completely biosafe nanocarrier to be active 
against cancer cells thus enabling the administration of a potential cancer 
therapy with no side effects. 
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Figure	 2.2.5	 Cell	 uptake	 (a)	 and	 viability	 (b)	 study	 on	 HT29	 cells	 after	 incubation	 with	 monolayer	
trilayer	and	pentalayer	NCs.	
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2.3	Conclusions	
The main goal of this research work was trying to redeem some of the 
limitations of liquid templates in the built up of polymer multilayer NCs, in 
order to take advantage of their unique properties.  
Based on the results obtained, in this work we propose a viable route that 
allows the use of a food grade NE stable enough to build up dimensionally 
controllable natural polymer multilayer NCs. These systems are of huge interest 
for nanomedicine.  
The liquid cores of the proposed NCs have a narrowly distributed size well 
under 200 nm, which has been achieved through an in-house consolidated 
method. Moreover, they show long-term stability, which effectively extends 
their shelf life and increases their application potential. These properties 
combined with an improved LbL procedure allowed for deposition of polymer 
layers directly at a liquid-liquid interface that is generally prevented by the 
instability of such liquid templates. This result provides a possible alternative to 
the LbL onto solid core templates.  
In order to add some other interesting features, efforts were devoted to 
increase the oil-core concentration during the LbL deposition of the multilayer 
NCs while preserving the dimensional properties. A 10% oil phase was welcome 
as a fulfilling compromise, also when compared to literature. Moreover, the 
polymer deposition method proved to be flexible by use of different kind of 
naturally derived polyelectrolytes such as hyaluronic acid, and sodium alginate. 
To highlight the advantage of pre-loading the NCs with relatively high 
amounts of lipophilic agents, we embedded curcumin in the oil-core without 
any post processing after multilayer deposition around the liquid template. 
These ready to use NCs demonstrated to be active against the human colon 
cancer cell line with a tunable time of action depending on the number of layers. 
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In conclusion, here we propose a reliable method to prepare robust and 
versatile lipid nanocarriers taking advantage of both liquid templates and LbL 
techniques. This stays still a relatively basic version of NCs, though. Many other 
appealing properties, such as multifunctional performance or on demand release 
of the payload, can be added to the NCs to increase their potential. Thanks to 
their multicompartment architecture, the possibility to finely engineer their 
polymer shell and to embed a number different molecules - which is limited 
only by one’s imagination - we believe that oil-core LbL NCs provide an avenue 
for the production of effective delivery systems in nanomedicine. 
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2.4	Materials	and	Methods	
Materials	
O/W NEs were prepared using Soybean oil (density at 20 °C of 0.922 g/ml) 
and surfactant Lipoid E80 (egg lecithin powder 80-85% enriched with 
Phosphatidyl choline (PC) and 7-9.5% content in phosphatidyl ethanolamine 
(PE)) purchased from Lipoid and used without further purification. Millipore® 
Milli-Q water was used for the preparation of all NEs and solutions. Chitosan 
(CT, LMW 90-150 kDa, DDA 84% determined via 1H-NMR) and heparin 
sodium salt from porcine intestinal mucosa (17-19 kDa), sodium alginate were 
purchased from Sigma Aldrich.  
Fluorescence imaging of multilayer NCs was performed tagging some 
chitosan layers with fluorophores, specifically with Fluorescein isothiocyanate 
(FITC) (m.w. = 389.38 g/mol) and Rhodamine B isothiocyanate TRITC (m.w. 
= 536.08 g/mol), both of them purchased from Sigma Aldrich and used without 
further purification. 
Additional polyelectrolytes such as hyaluronic acid and was kindly supplied 
by Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale" and used to 
enrich the polymer shell of multilayer NCs. 
The loading capability of the NCs was assessed by dissolving lipophilic 
model drugs such as Nile Red and Curcumin from Curcuma longa (Turmeric) 
powder (m.w. = 368.38 g/mol) purchased from Sigma-Aldrich and used with no 
further purification.  
 
Nanoemulsion	template	preparation	
NEs were prepared according to a two-step procedure previously developed 
[38]. First, a pre-emulsion and re-dispersion step is needed to achieve nanosized 
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and monodispersed O/W emulsions. While in a second step the narrowly 
distributed NE is coated with a positively charged chitosan layer, which 
contributes to significantly extend the stability of the system over time. This 
chitosan-coated NE has been named secondary NE. 
Briefly, in the first step the surfactant Lipoid E 80, and any possible 
lipophilic payload, is dissolved in a weighed amount of soybean oil under 
magnetic agitation until a homogeneous oil phase is observed. Then, the oil 
phase is added dropwise to a weighted amount of aqueous phase (Milli-Q water) 
and the two are mixed up with an immersion sonicator. This mixing process 
lead to a roughly dispersed O/W emulsion where the oil drops size is around 
500 nm. The emulsion is finally passed at 2000 bar through a high-pressure 
valve homogenizer (Microfluidics M110PS) for first three individual cycles - to 
strongly reduce the initial size - and then by re-filling the reservoir for 200 steps. 
This method was used for the preparation of 20 wt% O/W NEs. Two different 
concentrations of lecithin in oil were used in this study, namely 0.12, 0.24 
(w/w), respectively labled L90 and L130. 
Then, 0.1 M acetic acid solution of chitosan (0.125 wt%) was prepared and 
brought to pH 4 with the addition of NaOH. Each NE (L90, L130) 20 wt% oil 
phase was added to the chitosan solution quickly under vigorous stirring and 
kept under stirring for 15 min to allow uniform chitosan deposition. Final 
concentrations of oil and chitosan were 10 wt% and 0.1 wt%, respectively, while 
the pH of the final secondary nano-emulsions was 4. These NEs were properly 
re-dispersed by using the method reported in the previous work [38], stored at 
room temperature and analyzed over time. 
 
Polyelectrolytes	multilayer	deposition	
The previously described NE represents the oil template in the core-shell 
architecture of our NCs. We then grew a polymer shell around the liquid core to 
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enrich the NCs with further functionalities. To this aim we took advantage of 
the versatility of the layer-by-layer technique. According to this method, the 
multilayer structure was built up alternating polyelectrolyte layers of some 
negatively charged polymers (such as heparin, sodium alginate and hyaluronic 
acid) with the positively charged chitosan. The sequential deposition of the 
oppositely charged polymers led to the formation of eptalayer capsules in the 
case of L130 template and pentalayer capsules for L90. 
In order to highlight the multilayer structure of the NCs and provide a proof 
of concept of the deposition process, the last two chitosan layers of both 
eptalayer (L130 based) and pentalayer (L90 based) were labeled respectively with 
Rhodamine (TRITC) and Fluorescein (FITC). 
In order to prepare highly concentrated multilayer with a narrow size 
distribution, we developed a new methodology allowing for a higher control 
over the deposition process. Experimentally, the eptalayer and pentalayer NCs 
were prepared by aid of two syringe pumps (HARVARD APPARATUS 11 
PLUS) and an ultrasonic bath (FALC INSTRUMENTS).  Starting from the 
chitosan coated NE (10 wt% oil and 0.1 wt% chitosan), a negatively charged 
second polymer layer was deposited by mixing 1:1 (v:v) of a 0.175 wt% aqueous 
solution of heparin with the NE suspension. The two liquid phases were 
injected at the same flow rate (0.4 ml min-1) through two micrometric capillaries 
interfaced at their extremities. Each drop was then collected inside a glass tube 
immersed in the ultrasonic bath at room temperature, 59 kHz and 100% power. 
The same procedure was repeated also for the deposition of the subsequent 
polyelectrolyte layers according to the following concentration ratios: 
chitosan/heparin = 2.25 for the odd number layers and heparin/chitosan = 1.75 
for the even number layers. 
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Particle	size	and	Z-potential	characterization		
Size distribution and Z-potential of all the suspensions were measured by 
using the Dynamic Light Scattering (DLS) (λ = 632.8 nm) and particle 
electrophoresis techniques, respectively (Zetasizer NanoSeries, Malver).  
All the suspensions were diluted to a droplet concentration of approximately 
0.025 (wt%), using Milli-Q water in the case of NEs and multilayers ending with 
heparin. While the NCs ending with a chitosan layer were diluted in acetic acid 
Milli-Q water solution (pH 4; 20 mM).  
Z-potential measurements were performed to get indications about colloidal 
dispersion stability of all the suspensions. Also, it was a key method to follow 
the layer-by-layer procedure in building up of the polymer shell of the NCs. The 
successful deposition of each polymer layer was indeed confirmed by the 
potential reversal due to the alternation of polyelectrolytes of opposite charge. 
Furthermore, through Z-potential measurements it was also determined the 
proper amount of polyelectrolytes for each deposition step, which fully covers 
the surface of the NCs without exceeding in the dispersant phase. 
The Z-potential of all the suspensions was determined using a particle 
electrophoresis technique where the direction and velocity of droplet movement 
in a well defined electric field is monitored. Prior to analysis, all the suspensions 
were diluted in the same conditions as it was for the size measurement.  
 
Cryo-TEM	characterization	of	the	system	
The morphology of the NEs and multilayer NCs were observed by cryo-
TEM. In particular, frozen hydrated samples were prepared by applying a 3 µl 
aliquot to a previously glow-discharged 200 mesh holey carbon grid (Ted Pella, 
USA). Before plunging into nitrogen cooled liquid ethane, the grid was blotted 
for 1.5 s in a chamber at 4 °C and 90% humidity using a FEI Vitrobot Mark IV 
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(FEI company, the Netherlands). The particles were imaged using a Tecnai G2 
F20 transmission electron microscope (FEI company, the Netherland) equipped 
with a Shotky field emission gun operating at an acceleration voltage of 200 kV 
and recorded at low dose with a 2k x 2k Ultrascan (Gatan, USA) CCD camera. 
 
STED	analysis	of	nanocapsules	
NC size was also measured using super-resolution microscopy, i.e. stimulated 
emission depletion (STED). In order to preserve as much as possible the shape 
and the polydispersion of the NCs, we developed a procedure to prepare the 
samples for imaging with STED nanoscopy. Each sample was diluted (a 1:50 
dilution was chosen for the monolayers and a 1:12.5 dilution for the trilayers in 
order to have the same oil concentration of 0.02 wt%) in a heppendorf with a 
20 mM acetic acid buffer solution at pH 4 and was put in a FD3510 fluoro dish 
for 30 min to allow it to adhere to the surface of the dish. After that, 3 washes 
with a 5 wt% dabco antifade solution were performed and at the end the central 
part of the dish was left full of dabco during sample observation. In particular 
dabco antifade was needed to avoid the bleaching effect of the FITC-labeled 
chitosan. Samples were imaged by means of a Leica TCS STED-CW 
microscope (Leica-Microsystems, Mannheim, Germany). The resolution of the 
microscope was estimated to be < 80 nm. For each different sample, we 
acquired 10 images with a field of view of 25.6 x 25.6 µm for a pixel size of 25 x 
25 nm. The STED-CW beam power was 430 mW, measured at objective back 
focal plane. The image analysis was carried out by ImageJ software [41].  
Moreover, a STED analysis was also crucial to provide a further 
demonstration of the multilayer structure of the NCs polymer shell and of its 
tunability. This was achieved by a STED acquisition of the FITC-chitosan (last 
layer), and a confocal acquisition of TRITC-chitosan (underlying layer). 
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Cytotoxicity	assay	
Human colon cancer cells l (HT29 ATCC®) were seeded in a 96-well plates 
at a density of 3000 cells/well), cultured in Dulbecco's Modified Eagle's 
Medium and McCoy’s 5A medium (Sigma Aldrich, Milan, Italy) supplemented 
with 2 mM Glutamine (Gibco® Life Technologies, Monza, Italy), 10% Fetal 
Bovine Serum (FBS) (Gibco® Life Technologies, Monza, Italy) and 1% 
Penicillin Streptomycin (Gibco® Life Technologies, Monza, Italy).  Cells were 
then incubated for 24 h under standard conditions (5% CO2, 100% humidity, 37 
°C). 
The cytotoxicity of the formulations (monolayer, trilayer, pentalayer) was 
assessed on human colon cancer cells (HT29) by evaluating the activity of the 
mitochondrial dehydrogenase by of a modified MTT [3-(4,5-dimethyldiazol-2-
yl)-2,5 diphenyltetrazolium bromide] method according to the manufacturer’s 
instructions (Dojindo Molecular Technologies Inc., Rockville, MD). Human 
colon cancer cells were seeded in 96-well plates at a density of 10000 cells per 
well in complete medium at 37 °C in a humidified 5% CO2 atmosphere. For all 
the formulations, we performed time-course (from 24 up to 72 h) and dose-
response experiments (from 0.05 up to 30 µg/ml of curcumin). At the end of 
the incubation cells were washed three times with PBS (pH 7.4) and incubated 
with 100 µl of a MTT solution (0.5 mg/ml in cell culture medium) for 4 h. The 
absorbance was acquired at a wavelength of 450 nm with a Tecan Infinite M200 
plate-reader using I-control software. The relative cell viability (%) was 
calculated by the formula [A]test/[A]control×100, where “[A]test” is the 
absorbance of the test sample, and “[A]control” is the absorbance of the control 
cells incubated solely with culture medium. After the evaluation of cell 
cytotoxicity, we measured the total protein content by using the Micro BCA 
protein assay kit (Pierce). Briefly, cells were washed with ice-cold PBS, and 
incubated for 15 min in 150 µl cell lysing buffer (0.5% v/v Triton X-100 in 
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PBS), supplemented with 150 µl of Micro BCA protein assay kit reagent 
(prepared following the instructions of the manufacturer). Finally absorbance 
was measured at 562 nm with a plate reader. Cytotoxicity measurements were 
then normalized by the amount of total protein content in each well. 
 
Cell	uptake	analysis	
For uptake experiments HT29 cells were seeded were seeded in a 24-well 
plate at a density of 5x103 cells/well and allowed to grow for 24 h. The medium 
was then replaced with 500 µl of solution containing monolayer, trilayer and 
pentalayer with an equivalent curcumin molar concentration of 2.71 µM 
suspended in culture medium. Cells were then incubated for a time comprised 
between 0.5 and 24 h. Cells were then washed twice with PBS (pH 7.4), at the 
end of the experiments the supernatant was removed and the cells were washed  
three times with 10 mM PBS. Afterwards cells were lysed with 0.1 ml of 0.5% 
Triton X-100 in 0.2 N NaOH. The membrane-bound and internalized NEs 
were quantified by analyzing the fluorescence of the cell lysate (λexc= 420 nm, 
λem= 550 nm). Calibration was performed for each formulation dispersing the 
nanocapules with with a curcumin concentration of 10 µM up to 0.2 nM in a cell 
lysate solution (106 untreated cells dissolved in 1 ml of the Triton X-100/0.2 N 
NaOH solution). 
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2.5	Supplementary	Section	
Saturation	method	
For both the bilayer and the trilayer the optimal concentration of polymer to 
fully cover the NCs without exceeding was determined by saturation method. 
This methodology offers the great advantage to avoid post-processing 
procedures such as centrifuge and washing steps which typically follow the LbL 
deposition. Experimentally, the ratio between the concentrations of the polymer 
to deposit and the polymer already covering the NCs was increased until the Z-
potential of the suspension reached a plateau. In particular, the two graphs in 
Figures S1 show how for small ratios the amount of polymer added to the 
suspension only allows for a partial coating of the NCs which basically keep 
their initial surface charge. For example in Figures S1a, when the concentration 
of heparin employed to form a bilayer is only 0.5 folds higher than the 
concentration of chitosan coating the starting monolayer suspension, the Z-
potential of the monolayer just undergoes a slight decrease. Whereas, for higher 
ratios we observe the switch of the Z-potential from the positive values of the 
monolayer to the negative ones due to the formation of a heparin bilayer. Then, 
the ideal value of concentration of polymer to add is considered to be the first 
point of the plateau region. 
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Figure	 S1	 Identification	 of	 the	 optimal	 concentration	 ratio	 of	 two	 consecutive	 oppositely	 charged	
polyelectrolyte	layers	by	DLS.	
	
		
Zetasizer	analysis	of	multilayer	nanocapsules	
Primary NEs obtained according to the method reported in the Method 
section were characterized by DLS in terms of average size, polydispersity index 
and Z-potential. The results are summarized in Figure S2.  
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Sample	 Average	size	(nm)	 st.dev	 PDI	
Z-
potential	
(mV)	
st-
dev	
Monolayer	 138.4	 0.6	 0.059	 27.3	 1.0	
Bilayer	 138.6	 0.7	 0.059	 -39.6	 3.4	
Trilayer	 142.3	 2.3	 0.078	 27.1	 2.1	
Tetralayer	 139.2	 1.0	 0.070	 -37.6	 2.2	
Pentalayer	 145.2	 0.9	 0.095	 27.8	 1.7	
Esalayer	 142.6	 0.7	 0.093	 -35.2	 1.1	
Eptalayer	 147.5	 1.7	 0.099	 28.1	 0.7	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Average	size	(nm) st.dev PDI 
Z-
potential	
(mV) 
st-
dev 
Monolayer 100.9 2.2 0.076 22.1 0.5 
Bilayer 99.7 0.6 0.103 -38.4 4.6 
Trilayer 105.2 3.3 0.129 30.2 1.1 
Tetralayer 101.3 0.8 0.107 -41.2 3.8 
Pentalayer 106.0 1.5 0.132 25.9 1.2 
Sample Average	size	(nm) st.dev PDI 
Z-
potential	
(mV) 
st-dev 
Monolayer	 138.4	 0.6	 0.059	 27.33	 1.0	
Bilayer	 141.6	 1.2	 0.091	 -44.30	 4.6	
Trilayer	 144.7	 2.5	 0.086	 28.38	 3.6	
Tetralayer	 148.2	 5.0	 0.110	 -40.30	 1.4	
Pentalayer	 150.4	 4.1	 0.097	 26.08	 1.0	
b	
c	
a	
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Figure	 S2	 Average	 size,	 PDI,	 Z-Potential	 and	 size	 distribution	 of	 (a)	 FITC/TRITC	 eptalayer	 L130	
chitosan/heparin	(b)	FITC/TRITC	pentalayer	L90	chitosan/heparin,	(c)	pentalayer	L130	chitosan/alginate,	
(d)	 pentalayer	 L130	chitosan/hyaluronic	 acid,	 (e)	 pentalayer	 L90	chitosan/heparin	 loading	 NileRed,	 (f)	
pentalayer	L90	chitosan/heparin	loading	curcumin.	
Sample	 Average	size	(nm)		 st.dev		 PDI		
Z-
potential	
(mV)	
st-dev		
Monolayer		 138.4	 0.6	 0.059	 27.33	 1.0	
Bilayer		 140.1	 1.0	 0.078	 -36.21	 3.8	
Trilayer		 143.8	 1.6	 0.082	 27.43	 1.4	
Tetralayer	 148.8	 0.3	 0.085	 -31.27	 2.5	
Pentalayer	 149.8	 1.0	 0.083	 29.49	 2.2	
Sample Average	size	(nm)	 st.dev	 PDI	 
Z-
potential	
(mV) 
st-dev	 
Monolayer		 98.9	 1.6	 0.091	 18.5	 1.3	
Bilayer	 97.6	 0.8	 0.093	 -37.0	 1.3	
Trilayer	 100.5	 0.7	 0.113	 25.3	 2.5	
Tetralayer	 99.1	 0.2	 0.113	 -33.4	 3.9	
Pentalayer	 103.5	 1.4	 0.119	 24.7	 2.4	
Sample	 Average	size	(nm)		 st.dev		 PDI		
Z-
potential	
(mV)	
st-
dev		
Monolayer		 112.2	 1.4	 0.075	 36.5	 1.1	
Bilayer		 112.2	 1.1	 0.096	 -34.7	 1.0	
Trilayer	 116.3	 2.0	 0.120	 33.4	 2.1	
Tetralayer	 109.7	 1.1	 0.106	 -31.5	 0.7	
Pentalayer	 119.3	 1.1	 0.132	 34.6	 1.0	
d	
e	
f	
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Stability	over	time	of	multilayer	nanocapsules	
		
	
Figure	 S3	 Chitosan-hyaluronic	 acid	 pentalayer	 size	 (DH)	 stability	 over	 10	 months	 by	 DLS
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Chapter	3		
Stimuli-responsive	oil-core	nanocapsules	
	
	
Figure	 3.1	 A	 schematic	 representation	 of	 stimuli-responsive	 nanocapsules	 releasing	 their	 payloads	
upon	enzymatic	degradation	after	extravasation	in	tumor	tissue	by	EPR	effect.	
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Abstract	
In the war against cancer nanotechnology-based systems such as 
nanocapsules play a significant role by enhancing the efficacy of conventional 
therapies. Here we try to address some major limitations plaguing anticancer 
drugs, namely poor water-solubility and off-target toxicity. The delivery systems 
we propose are cross-linked polyelectrolytes nanocapsules based on an oil-core 
and a matrix metalloproteases-2 (MMP-2)-sensitive shell. They can load 
hydrophobic drugs and prevent their systemic leakage. Moreover, thanks to a 
stability enhancement strategy the system maintained its integrity in 
physiological conditions up to one month. On the other hand, some preliminary 
results suggest that the nanocapsules should release their payloads only when 
they reach the tumor microenvironment, which typically up-regulates MMP-2 
expression. These enzymes catalyze the disassembly of the nanocapsules, which 
are stabilized by an MMP-2-cleavable peptide sequence as cross-linker. This way 
the drug release should occur in a spatially controlled fashion upon an 
endogenous stimulus coming from the very nature of the tumor itself. 
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3.1	Introduction	
Although pretty much insight has been gained into tumor biology and giant 
leaps have been made in diagnostic devices, cancer still remains one of the most 
devastating diseases in the world and its treatment an open challenge. Current 
anticancer strategies are based on surgery, radiation and chemotherapeutic 
drugs, which often also kill healthy cells causing severe toxicity to the patient. 
Therefore, a new type of weapon in the war on cancer is needed. Typically, 
conventional chemotherapeutic approaches make use of poor water-soluble 
agents, which allow for very little control in terms of where they are distributed 
in the body and how fast they are cleared. This in turn implies a poor 
biodistribution and pharmacokinetics of the drug, which dramatically decrease 
its therapeutic index while increasing off-target toxicity.  
It is in this scenario that the concept of enhanced control and specificity has 
emerged as one of the main themes in nanomedicine [1] and a new generation 
of nanocarriers for the controlled and selective release of anticancer drugs has 
blossomed. The technological leap that especially the past decade has witnessed 
deals with on-demand drug delivery allowing for spatiotemporal and dosage 
control therapeutic profiles in response to specific stimuli [2]. These nanocarriers 
may be engineered to be sensitive to either exogenous or endogenous stimuli. 
For example, among the extracorporeal physical stimuli that can be applied, one 
can think to use light at a specific wavelength to trigger on-demand release from 
photosensitive systems [3]. The remote control of drug release can also be 
achieved by thermo- [4], magnetic- [5] or ultrasound-sensitive nanoparticulate 
systems [6]. 
On the other hand, it is also smart taking advantage of specific 
microenvironmental changes associated with neoplastic diseases to stimulate 
spontaneously tailored release profiles. The most explored options among 
potential endogenous stimuli associated to tumor microenvironment include the 
 52 
lowered interstitial pH [7], the altered redox potential due to higher glutathione 
concentration [8] and the up-regulation of certain enzymes such as matrix 
metalloproteinases (MMP) [9]. In particular, this proteolytic family of enzymes 
appears to play a central role in tumor angiogenesis, progression and invasion by 
remodeling of extracellular matrix (ECM) [10]. Therefore, the use of MMP 
cleavable peptides in conjugation with nanoparticle delivery systems holds great 
promise for the development of new therapeutic formulations. For example, 
MMP-2 enzymes (also known as gelatinase A; Mw: 72 kDa) hydrolyze type IV 
collagen, which is a major constituent of tumor ECM [11]. There are several 
examples in literature where MMP-2 are used as a trigger to promote selective 
drug release to tumors from nanocarriers engineered with peptide sequences 
sensitive to the catalytic activity of these enzymes [12] [9, 13].  
On the other hand, to improve the pharmacokinetics of the drug and reduce 
its side effects, it is also crucial to prevent systemic leakage of the payload from 
delivery systems. To this aim enhancing the stability of nanocarriers during 
blood circulation can really make the difference in the accumulation of the drug 
at the tumor site [14] [15]. 
Based on all these considerations, here we propose a strategy that attempts to 
face at one time two major issues related to the delivery of chemotherapeutic 
agents: the stability of the nanocarrier in the blood and the selective release of 
the drug to the target tissue. Following this aim, the main goal of this work is to 
provide NCs with two complementary features. On the one hand, we want to 
enhance NC stability in media where they could potentially undergo disassembly 
and thus lead to an uncontrolled release of the payload. On the other hand, we 
want to trigger the destabilization of the NCs once they explore a specific tumor 
microenvironment in order to promote the drug release. Thus, the delivery 
systems we propose are cross-linked polyelectrolytes NCs based on an oil-core 
and an MMP-2-responsive shell. In particular, their core/shell architecture is 
designed to encapsulate relatively large amounts of drug. The lipid core is based 
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on a monodisperse 20% v/v O/W NE, preloading Paclitaxel as a 
chemotherapeutic lipophilic agent. The polyelectrolyte shell adds potential to 
the bare liquid reservoir since it protects the payload from the outside, provides 
a hydrophilic interface and allows for a tunable release. The polymers we 
employ are nature-derived polysaccharides, namely chitosan and heparin which 
are assembled around the lipid core by a facile Layer-by-Layer (LbL) method 
[16]. This technique has emerged as one of the most versatile and controlled 
method to deposit ultrathin polymer layers around virtually any sort of 
templates, mainly driven by electrostatic forces among polyelectrolytes of 
opposite charge. True is that despite the several advantages offered by LbL, the 
only electrostatic interactions might turn out too weak for the stability of the 
NCs in physiological environment. Thereby, to prevent premature disassembly 
of the NCs and consequent systemic leakage issues, we provide a covalent 
stabilization by chemically cross-linking the polyelectrolytes pairs of NCs shell 
via click chemistry [14]. The chemical reaction we chose for this purpose is the 
thiol-ene click reaction, a metal catalyst-free approach to form a tioether bond 
between thiols and alkenes. Besides being highly biocompatible, this chemical 
reaction is performed under mild conditions and allows for elegant design of 
supramolecular structures [17] [18]. In this context, we use an MMP-2 sensitive 
peptide (Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln) [13] [19, 20] as chemical linker 
between the polymer layers of the shell. We have slightly modified this sequence 
in order to tag it with a fluorophore and allow for coupling reaction with 
heparin, on one side, and click reaction with cysteine-modified glycol chitosan, 
on the other side. Then, we assemble the pre-functionalized polysaccharides 
onto the NE template by LbL deposition and cross-link them through the 
peptide linker under UV light. This way we obtain NCs loading a powerful 
chemotherapeutic agent, which in principle are physically stable until they 
explore the higher concentration of MMP-2 within tumor microenvironment. 
The catalytic activity of the enzymes, indeed, induces the cleavage of the peptide 
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linker that has provided the enhanced stability to the NCs until then. The NCs 
undergo an MMP-2 mediated disassembly which promotes the release of the 
drug preferentially at the tumor site.  
In the light of these considerations, here we try to address the off-site 
toxicity big issue combining a stability enhancement and a stimuli-responsive 
drug release approach. The first prevents systemic leakage and off-target release 
through the cross-linking of the NC shell. The latter allows for a spatially 
controlled release of the drug through the cleavage of the MMP-2 sensitive shell 
preferentially in tumor microenvironment. This way drug release occurs upon an 
endogenous stimulus that comes from the very nature of the tumor itself.  
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3.2	Results	and	Discussion	
Solid	phase	peptide	synthesis	
In order to achieve a stabilization/destabilization mechanism for our NCs, 
we carefully designed a double-feature peptide linker to embed within the 
polymer layers of NC shell. In the first place, we identified an amino acidic 
sequence (Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln) that was sensitive to MMP-2 
catalytic activity. Then, we modified it by adding an allylated aspartic acid to 
perform thiol-ene click reaction with thiolated chitosan. We also introduced in 
the sequence an Mtt-lysine which provided the functional moiety to attach 
rhodamine B to the peptide side chain. Therefore, the resulting modified 
sequence is Lys-Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln-βAla-Asp(allyl) (see Figure 
3.2.1 for a schematic representation). 
 
 
Figure	3.2.1	MMP-2	peptide	sequence	modified	with	rhodamine	and	allylated	aspartic	acid.	
 
At the same time, we applied the same strategy for the preparation of a 
control sequence named RHOD-ctrlPEP (Lys-Leu-Gln-Gly-Ile-Gly-Pro-Gly-
βAla-Asp(allyl)), which differs from RHOD-PEP only for the disposition of the 
amino acids of active domain. We monitored the peptide during all the steps of 
its modification by mass spectrometry. In Figure 3.2.2 we report the mass 
spectra of the peptide after synthesis, coupling with rhodamine B and Fmoc 
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deprotection. First we confirmed the purity and quality of the peptide (Fmoc-
PEP) that we synthesized by a solid phase approach. In Figure 3.2.2a we report 
the molecular peak corresponding to the theoretic molecular weight of Fmoc-
PEP. Then, after removing the orthogonal Mtt protecting group from lysine in 
mild acidic conditions, we labeled the peptide with rhodamine B. The effective 
conjugation is confirmed by the second and third charge mass peak of FMOC-
RHOD-PEP (Figure 3.2.2a). Finally, we checked for complete Fmoc 
deprotection of the rhodamine labeled peptide (RHOD-PEP) before 
performing the coupling reaction with heparin. In Figure 3.2.2c RHOD-PEP 
exact mass and first and second charge are reported. Equivalent results were 
obtained also for the control peptide sequence (ctrlPEP). 
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Figure	 3.2.2	 Mass	 spectra	 of	 Fmoc-protected	 peptide	 after	 synthesis	 (a),	 Fmoc-protected	 peptide	
after	coupling	with	rhodamine	B	(b),	rhodamine	labeled	peptide	after	Fmoc	deprotection	(c).	Please	
note	that	the	 intensity	value	of	174.17013	recurring	 in	all	 three	spectra	corresponds	to	the	 internal	
standard.	
Heparin	–	rhodamine	peptide	conjugation	
In order to embed the MMP-2 sensitive linker within the polymer layers of 
the NCs we conjugated the modified peptide sequence with heparin. By 
condensation reaction between peptide N-terminus and heparin carboxylic acids 
moieties we achieved around 50 % substitution of the polymer chains. We 
174.17013
1287.68121
644.36688
Scan (6.469 min)
0
5
10
15
20
25
30×105
Counts vs Mass-to-charge (m/z)
0 200 400 600 800 1000 1200 1400 1600
174.17013
745.44502
1489.83057
497.31183
Scan (7.819 min)
0
5
10
15
20
25
30×105
Counts vs Mass-to-charge (m/z)
0 200 400 600 800 1000 1200 1400 1600
174.17013
856.95738
571.64682
Scan (10.638 min)
0
5
10
15×105
Counts vs Mass-to-charge (m/z)
0 200 400 600 800 1000 1200 1400 1600
a	
b	
c	
 58 
estimated such value by fluorimetric assay measuring rhodamine signal of the 
heparin-peptide conjugate (λex/ λem = 550/570 nm). We, indeed, correlated this 
fluorescence intensity to a rhodamine-peptide calibration curve acquired within 
a range of concentrations comprised between 0 and 0.065 mM (Figure 3.2.3). 
 
 
Figure	 3.2.3	 Calibration	 curve	 to	 calculate	 the	 substitution	 degree	 of	 heparin	with	 PEP-RHOD.	 The	
curve	was	recorded	by	a	spectrofluorimeter	measuring	the	fluorescence	intensities	from	solutions	at	
different	concentrations	of	PEP-RHOD.	
In Figure 3.2.4 we provide a schematic representation of the heparin 
peptide conjugate that for the sake of shortness we named HEP-RHOD-PEP. 
 
 
Figure	3.2.4	Heparin	functionalized	with	the	fluorescent	MMP-2	peptide.	
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Glycolated	 chitosan	 thiolation	 with	 N-acetyl-L-
cysteine		
Glycolated chitosan was partially substituted at the free amine groups with 
N-acetyl-L-cysteine (NAC) in order to provide the chains with thiol moieties. A 
typical amidation reaction was carried in presence of water soluble coupling 
agents, namely carbodiimide (EDC, ethyl-3-(3- dimethylaminoisopropyl)-
carbodiimide) and 1-hydroxy-1,2,3-benzotriazole (HOBt) (in Figure 3.2.5 a 
schematic representation of the chemical reaction is provided). Although this 
chemistry is widely used, it is rarely applied to polysaccharides especially in the 
case of chitosan, since it is difficult to substitute amine groups because of the 
poor solubility and reactivity of the polymer. The solubility issue was addressed 
using the glycolated chitosan in place of the LMW chitosan. In fact, the ethylene 
glycol moieties allowed for water solubility of the polymer even at neutral pH. 
On the contrary, LMW chitosan requires an acidic pH to reach complete 
dissolution through amines protonation. This constraint strongly limits the 
effectiveness of the coupling reaction, which in contrast requires a slightly basic 
pH in order to make the amines nucleophile. The degree of thiolation that was 
reached based on our scheme of reaction was assessed by Ellman’s test. This 
colorimetric assay, indeed, may highlight the concentration of free thiols by 
reaction with DTNB (also known as Ellman’s reagent), which absorbs at 412 
nm.  
 
Figure	3.2.5	Thiolation	of	glycol	chitosan	with	NAC	by	EDC/HOBt	chemistry.	
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The first step in the construction of the crosslinked polymer NCs was 
preparing an O/W NE pre-loading Paclitaxel. Following an optimized 
procedure (see chapter 2) we obtained narrowly distributed NEs, as shown by 
the DLS and the cryo-TEM reported in Figure 3.2.6a and b, respectively. The 
Paclitaxel (PXL) concentration in the overall volume of the NE was 37,5 𝜇g/ml 
(44 𝜇M). 
 
 
Figure	3.2.6	Average	size	of	PXL	loaded	NE	by	DLS	(a)	and	by	cryo-TEM	(b).	(Scale	bar:	100	µm).	
Starting from these oily templates we built our NCs assembling the modified 
polymers through a customized LbL procedure (see chapter 2 for more details 
on the method). First, we deposited a thiolated glycol chitosan (GC-NAC) layer 
on the negatively charged NEs. The GC-NAC monolayer NCs was then coated 
with a second layer of functionalized heparin. Finally, a last layer of GC-NAC 
was deposited. This way we obtained oil-core narrowly distributed trilayer NCs 
coated with naturally derived polyelectrolytes embedding an MMP-2 sensitive 
substrate. We shortly named this trilayer as MMP NCs. We also prepared two 
control series of trilayers based on non-functionalized heparin (HEP) and 
heparin modified with the control sequence peptide (HEP-ctrlPEP), which in 
the following will be recall as NF NCs and ctrlMMP NCs, respectively. The 
average size and the Z-potential of the three types of trilayer NCs at each step 
of the deposition process are summarized in Figure 3.2.7. It is noteworthy, that 
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these results were achieved following an optimized LbL deposition procedure 
(see chapter 2 for more details), which preserved the small size and narrow size 
distribution (PDI ≈ 0.1) of the starting NE. In fact, dealing with naturally 
derived polymers modified with sterically bulky pendant molecules, may really 
plague the deposition process. We also proved that the rhodamine labeled 
peptide was effectively embedded within the NC shell by confocal microscopy, 
as shown in Figure 3.2.8.  
 
 
Figure	 3.2.7	 Size	 distribution	 and	 Z-potential	 of	 the	 three	 types	 of	 trilayer	 NCs:	 MMP	 NCs	 (a,b);	
ctrlMMP	NCs	(c,d);	NF	NCs	(e,f).	
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Figure	3.2.8	Confocal	fluorescence	microscope	image	of	NCs	bilayer	coated	with	rhodamine-peptide	
modified	heparin.	(Scale	bar:10	µm).	
Stability	 enhancement	 of	 MMP-2	 trilayer	
nanocapsules	
We then exposed part of the as prepared trilayer NCs to UV light (λ = 254 
nm) in order to promote the formation of a tioether bond between the thiol 
moieties on GC-NAC and the alkene groups on the side chain of the peptide. 
The click reaction effectively brought to an enhancement of the trilayer stability 
through the crosslinking of the polymer layers. We performed the stability test 
by monitoring the size and the PDI of crosslinked and not-crosslinked trilayers 
in media with different pH and ionic strength, namely acid water (pH 4) and 
phosphate buffer (PBS 10 mM; pH 7.4). As highlighted by the size and PDI 
measurements reported in Figure 3.2.9a and b respectively, when dispersed in 
PBS, the crosslinked NCs show an initial swelling (≈ 100 nm), while the PDI 
does not seem affected by the change of medium. Moreover, this condition 
keeps constant over about one month. On the other hand the not-crosslinked 
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trilayers completely lose their dimensional characteristics after only one week 
increasing both their size and PDI in an uncontrolled fashion. Our explenation 
to this behaviour is that the change of medium causes an expected weakening of 
the electrostatic interactions between the layers of the NC shell. Due to the 
lower attraction, the oppositely charged layers get more distant form each other, 
thus leading to a larger NC size. However, only in the case of crosslinked NCs, 
the polymer layers are still hold together by some chemical linkages provided by 
the peptide linkers. These covalent constraints prevent the NC size to further 
increase, while keeping it to a costant value. This, in turn, would also justify a 
costant value of the PDI over time since the size increase is uniformely 
distributed among all the crosslinked NCs. 
 
 
 
Figure	3.2.9	Size	(a)	and	PDI	(b)	changes	over	time	both	in	acid	water	and	PBS	of	crosslinked	and	not	
crosslinked	(HEP-PEP)	NCs	by	DLS.	
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Cytotoxicity	 and	 Confocal	 Microscopy	 Imaging	 of	
MMP-2	Sensitive	nanocapsules		
To evaluate the cytotoxic effect of MMP-2 sensitive NCs and NF NCs when 
exposed to MMP-2 enzyme, preliminary tests were performed in vitro by means 
of Alamar Blue assay on HDF and U87 cells, which are healthy and tumor cell 
lines, respectively. The latter were chosen since they were already characterized 
in terms of MMP-2 expression levels and activity in a previous work of our 
group [19]. Figure 3.2.10 shows cell viability percentage of treated cells 
normalized to non-treated cells. MMP-2 sensitive NCs, pre-treated for 24 h with 
MMP-2 activated enzyme, showed a cytotoxic effect in all the cell types. On the 
other hand, a lower cytotoxic effect was observed for the MMP-2 sensitive NCs 
not pretreated with the enzyme. In particular, HDF and U87 cells after 24 h of 
exposure to MMP-2 sensitive NCs pre-treated with the enzyme showed 
respectively a 30% and 20% decrease in cell viability when compared to the 
control group. This gap is maintained constant increasing the incubation time. 
These data displayed a better performance of the enzyme pre-treated NCs, in 
which the shell is destabilized because of the peptide sequence that facilitates 
drug release from the core cleavage. This happens because, as already 
mentioned, the peptide sequence both stabilizes the NCs and provides the 
stimuli-responsive properties. Furthermore, these data are in accordance with the 
spectrofluorimetric analysis performed on the PS model NCs which show a 
RHOD content in the supernantat 5.3 fold higher for the treated NCs when 
compared to the untreated ones. Finally, control experiments were carried out 
treating cells with the non-functionalized NCs both in presence and absence of 
enzyme pre-treatment. Collectively we may observe a more relevant cytotoxic 
effect of the non-functionalized NCs compared to the MMP-2 responsive ones; 
this is probably due to the absence of the stabilizing element, namely the 
peptide. However, these preliminary results have to be supported by further 
experiments. To verify shell degradation after the exposure to the enzyme, 
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model PS core NCs were used for imaging analysis by confocal microscopy. 
These model NCs were chosen for this experiment since their solid core allows 
for a separation of the degraded shell from the core through centrifugation (see 
Material and Methods section).  
In particular, HDF and U87 cells were observed by confocal microscopy 
after 24 h of incubation with PS nanoparticles as negative control, enzyme 
treated and enzyme untreated PS core MMP-2 sensitive NCs and enzyme 
treated and enzyme untreated PS core ctrlMMP NCs. 
Figure 3.2.11 and 3.2.12 show NCs distribution in HDF and U87 cells 
respectively. 
Figure 3.2.11b and 3.2.12b shows the presence of a diffused cytoplasmic 
green fluorescent signal due to nanoparticle uptake by the cells. 
Figure 3.2.11c, 3.2.12c and 3.2.11d, 3.2.12d show cells treated with MMP-2 
sensitive NCs with and without the enzyme treatment, respectively. In 
particular, in panel c only a spotted green fluorescent signal is visible, while 
panel d displays a yellow spotted fluorescent signal due to the co-localization 
between the green signal of the PS core and the red signal of the RHOD-
peptide that composes the NC shell.  
Finally, Figure 3.2.11e, 3.2.12e and 3.2.11f, 3.2.12f show cells treated with 
ctrlMMP NCs with and without the enzyme treatment, respectively. All the 
panels show a yellow spotted fluorescent signal derived from the co-localization 
of the green signal of the PS core with the red signal of the RHOD-peptide that 
composes the NC shell.  
Since co-localization occurred in both cases, we may assume that the enzyme 
pre-treatment did not cause the disassembly of the NC shell. This happens 
because the ctrl peptide is not specific for MMP-2 enzyme cleavage. 
Taken together these preliminary results clearly show that the enzyme pre-
treatment of the MMP-2 sensitive NCs causes a disassembly of the shell that 
does not occur without the enzyme treatment. Moreover, the enzymatic 
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disassembly of the shell only occurs if the NCs are functionalized with an MMP-
2 sensitive peptide sequence. 
 
	
Figure	 3.2.10	 Cytotoxicity	 assay	 of	MMP-2	 sensitive	 NCs,	 the	 figure	 shows	 cell	 viability	 of	MMP-2	
sensitive	NCs	pre-treated,	non-functionalized	NCs	and	non-functionalized	NCs	pre-treated	in	HDF	and	
U87	cells	after	(a)	24	and	(b)	48	h	of	incubation.	Cell	viability	was	expressed	as	percentage	compared	
to	control	cells.	
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Figure	3.2.11	Confocal	 images	of	HDF	cells.	HDF	cells	 (a),	cells	 treated	with	PS	 (b),	MMP-2	sensitive	
pre-treated	NCs	(c),	MMP-2	sensitive	NCs	(d),	ctrlMMP	NCs	non-treated	(e)	and	ctrlMMP	NCs	(f)	after	
24	 h	 of	 NCs	 exposure.	 PS	 nanoparticles	 are	 in	 green,	 RHOD-peptide	 is	 in	 red	 and	 cell	 nuclei	 and	
cytoplasm	 is	 in	 blue.	 Colocalization	 of	 RHOD-peptide	 and	 PS	 nanoparticles	may	 be	 seen	 in	 yellow.	
(Scale	bar:	75	µm).	
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Figure	 3.2.12	Confocal	 images	of	U87	cells.	U87	cells	 (a),	cells	 treated	with	PS	 (b),	MMP-2	sensitive	
pre-treated	NCs	(c),	MMP-2	sensitive	NCs	(d),	ctrlMMP	NCs	pre-treated	(e)	ctrlMMP	NCs	(f)	after	24	h	
of	NC	exposure.	PS	nanoparticles	are	in	green,	RHOD-peptide	is	in	red	and	cell	nuclei	and	cytoplasm	is	
in	blue.	Colocalization	of	RHOD-peptide	and	PS	nanoparticles	may	be	 seen	 in	yellow.	 (Scale	bar	 :75	
µm).	
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3.3	Conclusions	
In this work we focused on one of the major concern related to the 
administration of anticancer drugs, namely off-target toxicity. Although 
nanomedicine struggles to find always-new nanotechnology based solutions, 
there is still a tremendous need for drug delivery systems capable to maximize 
the therapeutic index and to drastically reduce side effects.  
To this aim we designed and prepared stabilized oil-core polymer NCs 
allowing for a spatially controlled release of their payload in response to an 
endogenous stimulus coming from the very nature of the tumor.  
Thus we pre-loaded a finely dispersed O/W NE with a relatively large 
amount of a common chemotherapeutic agent. Then we coated the NE with 
nature-derived polymers that we had previously modified to allow for their 
chemical crosslinking based on a catalyst free click chemistry approach.  
This way we obtained narrowly distributed polymer NCs showing enhanced 
stability in physiological media over 1 month compared to their basic LbL 
counterparts.  
Furthermore, the NCs demonstrated to be responsive to the catalytic activity 
of MMP-2, undergoing a disassembly of their polymer shell after exposure to 
the enzymatic environment. Indeed, to achieve a tumor site-specific drug release 
mechanism we used an MMP-2 sensitive peptide as cross-linker between the 
polymer layers. Therefore, the NCs keep their stability until they reach the 
tumor microenvironment where MMP-2 are usually up-regulated so that it is the 
tumor itself that triggers the release of the drug. 
In conclusion, this strategy may be a viable route to address with a single 
elegant solution both the NCs stability issue and the spatially controlled release 
requirement, thus contributing to increase the efficacy of the current anticancer 
therapies. 
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3.4	Future	Perspectives	
The results of the biological assays stem from an early step in understanding 
NCs behavior in physiological-like conditions. In particular, a more complex in 
vitro cancer model may be used to test the NCs performance. In this context 
tumor spheroids are, for example, a relevant in vitro model able to better mimic 
the 3D tissue architecture if compared to standard 2D models [19]. In this case, 
it would be possible to test NCs cytotoxicity as a function of endogenous MMP-
2. In particular, the use of two diverse cell lines expressing different levels of 
endogenous MMP-2 may help to better understand NCs ability to trigger a 
specific release in response to an endogenous stimulus usually overexpressed in 
tumor tissues. 	
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3.5	Materials	and	Methods	
Materials	
Chitosan low molecular weight (CT-LMW, 90-150 kDa), heparin sodium salt 
(from porcine intestinal mucosa), 1-hydroxybenzotriazole hydrate (HOBt), 
acetic acid, sodium acetate, sodium chloride, N-acetyl-L-cysteine (NAC), 
allylamine, sodium nitrite, methanol, ammonium hydroxide solution, sodium 
borohydride, hydrochloric acid, sodium hydroxide, deuterium oxide (D2O), 
dithiobis(2-nitrobenzoic acid) (DTNB), fluorescein isothiocyanate (FITC), N-(3-
Dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC), O-benzo-
triazole-N,N,N,N’-tetramethyluroniumhexafluorophosphate (HBTU), N,N-
diisopropylethylamine (DIPEA), anhydrous N,N-dimethylformamide (DMF), 
piperidine, trifluoroacetic acid (TFA), Triisopropylsilane (TIS), dichloromethane 
(DCM),  2-(N-Morpholino) ethanesulfonic acid (MES) sodium salt, HEPES, p-
aminophenylmercuric acetate (APMA), acetonitrile (ACN) HPLC grade water, 
1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU reagent) and buffer solutions were obtained from 
Sigma–Aldrich (Saint Louis, MO). Recombinant Human Matrix 
metalloproteinase-2 (MMP-2) was purchased from Peprotech Inc. (Rocky Hill, 
NJ). Soy-bean oil (density at 20 °C of 0.922 g/ml) and Lipoid E80 lecithin (egg 
lecithin powder 80 85% enriched with phosphatidyl choline and 7-9.5% content 
in phosphatidyl ethanolamine) were purchased from Lipoid. Glycol chitosan 
(GC) was purchased from Wako Chemicals. Carboxyl latex beads (4% (w/v), 
0.1 µm) and FluoSpheres® (Carboxylate-Modified Microspheres, 0.1 µm, yellow-
green fluorescent (505/515), 2% solids) were purchased from Invitrogen. 
Dialysis membranes were purchased from Spectrum Laboratories Inc. 
 
 72 
Peptide	synthesis		
MMP-2 sensitive peptide (NH2-Lys-Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln-βAla-
Asp(allyl)-COOH) was synthesized in a modified version, with a 4-Methyltrityl 
(Mtt) protected lysine at the N-terminal, and a beta alanine spacer  and an 
allylated aspartic acid at the C-terminal. It was employed the solid-phase method 
and standard Fmoc strategies. Rink-amide resin (substitution 0.7 mmol/g) was 
used as solid support. Activation of amino acids was achieved using 2-(1H-
Benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate: 
hydroxybenzotriazole: N,N-diisopropylethylamine (HBTU/HOBt/DIEA) (1 : 1 
: 2). All couplings were performed for 15 min and deprotections for 10 min. 
Peptides were not removed from the resin, after acetylation step to allow 
coupling reaction with rhodamine while still attached. Peptides purity and 
identity were confirmed by LC-MS (Agilent 6530 Accurate-Mass Q-TOF 
LC/MS spectrometer). Purified peptide was lyophilized and stored at 4 °C until 
use.  
Reagents for peptide synthesis (Fmoc-protected amino acids, resins, 
activation, and deprotection reagents) were from Iris Biotech GmbH. 
 
Labeling	reaction	
Before the coupling reaction of peptides with rhodamine, the Mtt group 
protecting the side chain of the lysine residue was selectively removed using 1% 
TFA in DCM plus 1-5% TIS for quenching the trityl cations released. These 
conditions allowed the peptide to remain attached to the support although Rink 
amide is an acid-labile resin. 
Pre-swelled dry resin (100 mg) was repeatedly rinsed with the as prepared 
deprotection mixture of solvents 2 minutes and flushed. Complete deprotection 
of amines was assessed by Kaiser test and mass spectrometry.  
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For labeling reaction, carboxylated rhodamine and activating agents 
(EDC/HOBt) (excess 2 with respect to the theoretic mass of peptide) was let 
reacting overnight with the pre-swelled dry resin in DCM containing DIPEA. 
At the end of reaction the resin was washed several times with DMF and the 
last 6 washes were performed alternating DCM and Methanol. In order to check 
for left free amines in the side chain of the peptide, Kaiser test and LC/MS were 
performed at the end of reaction. Then, only before coupling reaction with 
heparin, the peptide was deprotected from Fmoc at the N-terminus and 
removed from the resin. Experimentally, Fmoc groups were removed with 20% 
piperidine solution in DMF. After washing, Kaiser test was performed to detect 
that all the N-terminus amines were free.  
Peptides were removed from the resin by treatment with a TFA/TIS/H2O 
(95 : 2.5 : 2.5, v/v/v) mixture for 90 min at room temperature, then, crude 
peptide was precipitated in cold diethyl-ether, dissolved in a water/acetonitrile 
(1:1, v/v) mixture, freeze-dried for 48h and stored at -20°C. 
All the procedures described for both the synthesis and the labeling of the 
peptide were applied also to the control sequence peptide. 
 
Heparin	-	peptide	coupling	reaction	
The condensation of the carboxylic acids of heparin chains with the peptide 
N-terminus was carried in slightly basic conditions using a classic EDC/NHS 
chemistry.  
In a typical procedure, heparin (10 mg, 1 equiv) was dissolved in 1 ml of 
carbonate buffer (pH 7.8). Then, 3.4 mg (22 equiv) of EDC*HCl were added 
and the solution was stirred at room temperature for 30 min. Two milligrams 
(22 equiv) of NHS were then added, and the solution was stirred at room 
temperature for 3 h. Twenty-one point nine milligrams (1 equiv) of rhodamine-
labeled peptide were added, and the mixture was stirred overnight. Then, the 
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product of reaction was dialyzed using a 6-8 kDa bag against a mixture 
ACN/water 30:70 for 48 h. The purified conjugate was finally freeze-dried and 
stored at -20°C. 
The substitution degree of heparin was assessed by measuring the 
fluorescence intensity of the rhodamine-peptide after calibration with a water 
solution of rhodamine-peptide at different concentrations using a 
spectrofluorimeter (EnSpire 2300 PerkinElmer).  
	
Oil-in-Water	nanoemulsion		
The O/W nano-emulsion was prepared as previously described (see chapter 
2). Briefly, the oil phase was prepared by adding an exact amount of Lipoid E 80 
to the soy-bean oil at 60 °C and then sonicated with an immersion sonicator 
(Ultrasonic Processor VCX500 Sonic and Materials). To obtain the pre-
emulsion, the oil phase was added dropwise to a weighted amount of aqueous 
phase (Milli-Q water) and mixed using the immersion sonicator. The pre-
emulsion was finally passed at 2000 bar through the high-pressure valve 
homogenizer (Microfluidics M110PS) to obtain the final nano-emulsion.  
	
Modification	of	glycol	chitosan	with	N-Acetylcysteine		
Thiolation was performed on glycol chitosan (GC, chitosan conjugated with 
ethylene glycol) according to a procedure previously reported [21]. In the typical 
procedure, 0.5 mmol of the chitosan substrate were dissolved in 10 ml of Milli-
Q water. In the first place, the pH was adjusted to a value of 4 with HCl 1 M to 
allow complete dissolution. Then, amounts of NAC and coupling agents were 
added to the solution according to the following molar ratio HOBt : GC : NAC 
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: EDC = 1 : 1 : 4 : 16. Then the pH was raised and maintained to a value of 6.8 
throughout the reaction time (6 h). The reaction proceeded at room 
temperature. The product was then purified by dialysis four times against water 
containing 1% (w/v) NaCl and acidified with HCl at pH = 3, four times against 
water acidified at pH = 3. Finally, the purified product was freeze-dried for 48 
h.  
Total and free thiols were determined using a colorimetric assay, the Ellman's 
test. In particular, after reaction of thiolated chitosan with a DTNB solution at 
25 °C for 2 h, absorbance was registered at 412 nm using a Varian Cary Scan 
100 Spectrophotometer.  
	
LbL	 deposition	 of	 functionalized	 polymers	 on	 O/W	
nanoemulsion		
Monolayer, bilayer and trilayer were obtained by a customized LbL 
deposition procedure already reported in the materials and methods section of 
chapter 2. Briefly, the trilayer NCs were prepared by aid of two syringe pumps 
(HARVARD APPARATUS 11 PLUS) and an ultrasonic bath (FALC 
INSTRUMENTS) under specific flow and ultrasounds conditions. Starting 
from the negatively charged NEs a GC-NAC layer was first deposited. Then, a 
negatively charged second layer was deposited by mixing the monolayer 
suspension with a HEP-RHOD-PEP aqueous solution. Finally, the bilayer was 
mixed with a solution of GC-NAC to give the MMP-2 responsive trilayer with 
the following final concentrations: 0.25% wt% oil - 0.025 wt% GC-NAC - 
0.0069 wt% HEP-RHOD-PEP - 0.02 wt% GC-NAC. The same procedure for 
the preparation of trilayer NCs was followed also using the control peptide 
modified heparin (HEP-RHOD-ctrlPEP) and the non functionalized heparin 
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(HEP) the trilayers were prepared following but with the same final trilayer 
concentrations as for the one prepared with HEP-RHOD-PEP. 
 
LbL	 deposition	 of	 functionalized	 polymers	 on	
polystyrene	carboxylated	nanoparticles		
The same procedure described in the previous paragraph was employed for 
the assembly of all the three kinds of trilayers also around polystyrene 
nanoparticles (PS NPs) for imaging purposes. In this case the final 
concentrations for all the three kinds were: 0.04% wt% PS NPs - 0.032 wt% 
GC-NAC - 0.0064 wt% HEP-RHOD-PEP - 0.032 wt% GC-NAC.   
	
Photoreaction	of	the	multilayer		
The trilayer NCs made with both kinds of the modified heparin (rhodamine-
peptide heparin and rhodamine-control peptide heparin) were irradiated with 
UV light for 2 h using a UV Hand Lamp Spectroline® E-Series UV lamp 
(output 6 W, wavelength 254 nm). The light source was at 3 cm distance. 
Photoreaction was conducted without a photoinitiator.  
 
Particle	size	and	Z-potential	characterization		
The setting parameters for both Particle size and Z-potential measurements 
were the same as described in chapter 2. All the suspensions were diluted to a 
droplet concentration of approximately 0.025 (wt%), using Milli-Q water in the 
case of NE and multilayers terminating with heparin. While the NCs terminating 
with a chitosan layer were diluted in acidified Milli-Q water solution (pH 4).  
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Stability	 tests	 on	 crosslinked	 and	 not	 crosslinked	
trilayers		
The stability test of the NCs over time was performed dispersing both the 
crosslinked and not crosslinked trilayers in different media, i.e. water at pH = 4, 
PBS 10 mM pH = 7.4. Stability was determined monitoring by DLS particle size 
variations over time.  
 
Confocal	analysis	of	trilayer	nanocapsules	
Trilayer on O/W nano-emulsion was diluted 1:25 to a final oil concentration 
of 0.01 % w/v in an Eppendorf with PBS 10 mM at pH 7.2 and 200 μl were 
put in a FD3510 dish for 30 min to allow it to adhere to the surface of the dish. 
After that, several washes were performed replacing the sample twice with 120 
μl of water. Samples were imaged with a Leica TCS STEDCW microscope 
(Leica-Microsystems, Mannheim, Germany) equipped with an oil immersion 
100× objective. Images were acquired with a field of view of 25.6 × 25.6 μm 
for a pixel size of 25 × 25 nm. The analysis of the images was carried out using 
LAS AF software.  
 
Cell	culture	
To test the biological effect of the NCs, human glioma cell line (U87-MG), 
and primary human dermal fibroblasts (HDF) were used as models of tumor 
and healthy tissues respectively [20].  
 78 
HDF cells were cultured in Eagle’s minimal essential medium (EMEM) 
supplemented with 20% Bovine Serum Albumine (FBS, Gibco), 100 U/mL 
penicillin, 100 mg/mL streptomycin and 2X non-essential aminoacids. U87-MG 
cells were cultured with EMEM supplemented with 10% FBS and antibiotics.  
Both cell lines were maintained in 100 mm diameter cell culture in a 
humidified controlled atmosphere with 95% to 5% ratio of air/CO2, at 37 °C. 
The medium was changed every 2–3 days. 
 
Nanocapsules	in	vitro	enzymatic	treatment	
To observe the effect of the enzymatic cleavage of the NC shell on its drug 
release and cell-internalization, NCs were treated in vitro with 40 nm MMP-2 
enzyme. In particular, for cytotoxicity experiments, oil-core NCs were used, 
while PS core NCs were used for uptake analysis by confocal microscopy. 
Before NCs treatment, the enzyme was activated according to the 
manufacturer’s procedure. Briefly, the enzyme (1 Eq) was activated for 3 h at 37 
°C by 100 mM APMA solution in Tris–HCl 50 mM, pH 7.2 (45 Eq), at a final 
enzyme concentrations of 40nM 
NCs were then diluted in a MMP-2 buffer solution (50mM HEPES, 200mM 
NaCl, 10mM CaCl2, 1mM ZnCl2, pH 7.4) [19] and incubated for 24h at 37 °C 
in continuous stirring in presence and absence of the enzyme, to allow the 
enzymatic degradation of the shell.  
For viability test, treated and untreated NCs were diluted in culture medium 
to a final PXL concentration of 100 nM. 
For confocal microscopy imaging, NC suspension was centrifuged at 13,000 
rpm for 30 min. Then, the supernatant was carefully removed and collected for 
further analysis and the NCs were resuspended in cell culture medium by means 
of an ultrasonic bath (59 Hz, 100% Power, 15 min). The supernatants were then 
analyzed for Rhod content by a spectrofluorimeter. Samples were read in 
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triplicate and the linearity of the response was verified over the 0 – 0.065 mM 
RHOD-PEP concentration range (r2>0.99). 
 
Cell	viability	
Cells were seeded in 96 well microplates at a density of 104 cells/well and 
incubated for 24 h in a humidified atmosphere at 37°C and 5% CO2 to obtain a 
subconfluent monolayer.  
As already mentioned, for cell viability analysis oil-core nanoparticles were 
used. In particular, cells were treated with non-functionalized and MMP-2 
sensitive NCs which were diluted in culture medium to a final PXL 
concentration of 100 nM. In both cases enzyme-treated and enzyme-untreated 
samples were tested. Cells were also treated with cell medium alone as positive 
control. 
The metabolic activity of both cell lines was determined after 24 h and 48 h 
of exposure by using standard Alamar Blue assay (Life Technologies, Grand 
Island, NY) according to the manufacturer’s procedure. Data represent the cell 
viability percentage of treated cells normalized to non-treated cells. All the 
experiments were performed in triplicate. 
 
Confocal	 microscopy	 imaging	 of	 MMP-2	 sensitive	
nanocapsules	in	cells	
4x104 HDF and U87 cells were seeded in 35 mm glass bottom dishes 
(WillCo-Wells) and incubated for 24 h in a humidified atmosphere at 37°C and 
5% CO2 to obtain a subconfluent monolayer. After that, cells were incubated 
for 24 h with treated and non-treated PS-core NCs. The samples were the same 
used for the cytotoxicity assay but in this case the negative control corresponded 
to uncoated bare PS nanoparticles. Then, samples were washed twice with PBS 
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to remove non internalized NPs and fixed with paraformaldehyde 4% for 10 
min. Finally, cell nuclei were stained with DRAQ5 (Abcam). Samples were 
observed by confocal multiphoton microscope (Leica TCS SP5 MP, Solms, 
Germany) with a 25x oil immersion objective. Images were acquired with a 
resolution of 1024x1024 pixels. 	
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Chapter	4	
Graphene	oxide	oil-core	nanocapsules	
	
	
Figure	 4.1.1	A	 scanning	electron	microscope	 image	of	a	drop	of	graphene	oxide	after	 freeze-drying	
process. 
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Abstract	
Graphene oxide (GO) is gradually breaking the taboo of its application into 
the biomedical field. The outstanding optical properties and the unparalleled 
loading capacity make GO a key nanomaterial for several medicine and 
biotechnology offshoots ranging from bioimaging to stimuli responsive drug 
delivery and photo-thermal therapy. However, combining all these intriguing 
features into a multimodal therapeutic platform still proves challenging. To this 
aim, very little has been done for the integration of GO into nanosized drug 
delivery systems and the only relevant cases deal with the Layer-by-Layer 
deposition of GO on sacrificial template microcapsules. Moving from these 
considerations, here we report on some preliminary results we achieved starting 
from commercially available GO together with a robust platform for the 
preparation of ultrastable liquid nanocapsules. First we chemically and 
mechanically treated GO to obtain fluorescent nanosheets, which we then 
integrated onto monodisperse O/W nanoemulsions by facile LbL technique. 
This way we prepared GO coated nanocapsules that we preloaded with a 
chemotherapeutic agent. When incubated with two cell lines (healthy and 
tumor) the NCs showed strong non-linear fluorescence in the cell nuclear region 
under two-photon excitation. These results unfold some interesting scenarios 
including the chance to track the fate of the drug delivery system after its 
administration. 	 	
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4.1	Introduction	
Why is there so much noise around the word graphene? What does it make 
this relatively young material so special to a certain research community eyes, 
while some others stay skeptical and do not actually feel the hype?  
Whatever your stance, graphene has already invaded virtually every 
nanotechnology offshoots, with uncountable potential applications inching their 
way into a near-future marketplace.  
At a first glance, probably most of the paradigm-shifting fascination 
attributed to graphene depends on its condensed matter: it is the first two-
dimensional material that has been physically isolated! Its name, indeed, is 
referred to a flat monolayer of sp2-hybridized carbon atoms tightly packed into a 
honeycomb lattice. Although scientists were theorizing about one atom thick, 
two-dimensional crystals since 1970s, freestanding graphene was presumed not 
to exist mainly due to thermodynamic instability. Thereby, its finding by 
Novoselov and Geim in 2004 [1, 2] suddenly disclosed all its potential, also 
paving the way for other two-dimensional crystals (i.e. phosforene [3], 
germanene [4], silicone [5] and so on). The unique nature of its charge carriers 
[6, 7] and their interaction with the crystal lattice is mainly responsible for the 
huge deal of research interest. A deep understanding and fine control of 
graphene zero-band gap electronic structure (see Figure 4.1.2) and ballistic 
conduction could actually open up new opportunities in several key 
technological fields and also contribute to the development of a novel platform 
with important social and economic impacts. 
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Figure	 4.1.2	Mind	 the	Gap!	 (a)	 Classification	of	materials	 based	on	 their	 conductive	properties	 and	
relative	energy	band	gap.	(b)	Distinction	between	semiconductors	and	graphene	behavior	highlighting	
the	 almost	 zero	band	gap	of	 the	 latter.	 (c)	 Left:	 lattice	 structure	of	 graphene.	 Right:	 corresponding	
Brillouin	zone.	 (d)	Graphene	band	structure	and	a	zoom	 in	of	 the	energy	bands	close	 to	one	of	 the	
Dirac	points.	 (Figures	 readapted	 from:	 (a)	http://www.azonano.com/article.aspx?ArticleID=4264;	 (b)	
http://nauka.in.ua/upload/medialibrary/651/651c83f718b2a807c335d2cbbf396a96.jpg;	 (c)	 ref.	 [7];	
(d)	http://www.th.u-psud.fr/.	
Among the most mind-blowing opportunities potentially enabled by 
technological translation of graphene intriguing properties, there are stretchable 
electronics (flexible and wearable devices), ultrasensitive sensors, high frequency 
devices (THz), and ultradense data storage (for more examples see Table 4.1.1). 
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Table	 4.1.1	 A	 schematic	 correlation	 between	 graphene	 properties	 and	 their	 possible	
technological	conversion	with	relative	impact	on	society.	(Table	readapted	from	ref	[8]).		
 
 
 
More recently, the chemically derived forms of graphene have also received 
much attention, especially graphene oxide (GO) due to several advantages, not 
least the preferred routes for a large-scale manufacturing. Indeed, a viable way 
to produce graphene materials is by chemical exfoliation of graphite under 
strong oxidizing conditions [9, 10]. This way in GO, the 100% sp2 two-
dimensional network of pristine graphene becomes a mixture of sp2 and sp3 
bonded carbon atoms. In particular, the oxygen defects within graphene surface 
are introduced in the form of epoxy and hydroxyl groups covalently bonded 
with the sp3 hybridized carbon atoms. Whereas, the remaining fraction of sp2 
hybridized carbon atoms are bonded either with neighboring carbon atoms or 
with oxygen in the form of carboxyl and carbonyl groups. The latters are located 
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mostly at the edges of the GO sheets (see Figure 4.1.3 for a schematic 
representation). As a first consequence, the presence of these functional groups 
within GO sheets make it hydrophilic thus allowing its dispersion in water [11], 
in contrast to pristine graphene. This prerogative combined to the outstanding 
optoelectronic and photothermal properties arising from GO unique 
heterogeneous atomic and electronic structure, is breaking the taboo of studying 
graphene-derived materials for nanomedicine and biotechnology applications 
[12, 13]. 
 
 
Figure	4.1.3	The	structures	of	graphene	and	graphene	oxide	(Figure	redrawn	after	ref	[12]).	
Of course, the use of carbon nanomaterials in the biomedical field has raised 
much of debate mainly due to safety issues. Several cytotoxicity studies revealed 
many possible mechanisms induced by GO including hemolytic activity [14], cell 
starvation [15], generation of reactive oxygen species (ROS) and apoptosis [16]. 
On the other hand, there are examples where by means of PEGylation and a 
lower graphene dose, no significant toxic effects are observed on the long term 
[17]. True is that the current stage of research on toxicity of GO is still in its 
infancy and the relevant data are rather scattered. In the meanwhile, all the 
potential GO shows in the biomedical research area keeps on legitimize its 
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investigation. In particular, its huge surface area disseminated with aromatic 
rings enables high loading of hydrophobic molecules simply by van der Waals or 𝜋 – 𝜋 interactions, thus making GO an ideal candidate for the delivery of water-
insoluble aromatic anticancer drugs [18].  
Another appealing feature of GO for nanomedicine is its strong optical 
absorption in the near-infrared (NIR) region of light (700-900 nm), which is a 
tissue transparency window ideal for optical imaging and phototherapies. The 
heat generated by GO upon irradiation, indeed, can be exploited in cancer 
therapy for hyperthermia treatment [19] as well to trigger drug release from heat 
responsive nanocarriers [20]. 
Furthermore, GO broad fluorescence has been lately highlighted and 
investigated. Several works have shown that the fluorescence of GO can be 
observed and tuned by modifying the content of oxygen-containing groups or 
by reducing its size to the nanometer scale [11, 21-25]. However, it is 
noteworthy that most of this research is focused on the luminescence induced 
by continuous-wave lasers through one-photon excitation and with emission in 
the near-UV/visible band. Whereas, only few papers report on two- or multi-
photon fluorescence induced with a NIR laser [26-28], which is of real interest 
for nanomedicine and biotechnology applications. This microscopy technique, 
indeed, allows for reduced photobleaching and phototoxicity, minimized tissue 
auto-fluorescence background, and deep tissue penetration as a consequence of 
low Rayleigh scattering and low tissue absorption of NIR light [29]. True is that 
due to the strong heterogeneity of GO atomic and electronic structure there is 
still a lack of knowledge around the origin of its fluorescence. What is clear is 
that GO nanosheets are a mixture of sp2 and sp3 domains where sp2 nanoislands 
are immersed and localized in an sp3 matrix. Therefore, one of the most 
accepted explanations sees fluorescence arising from the electrons/holes 
recombination as a consequence of a quantum confinement effect [4, 21] (see 
Figure 4.1.4 for a schematic representation). 
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Figure	4.1.4	Schematic	band	structure	of	GO.	Smaller	sp2	domains	have	a	larger	energy	gap	due	to	a	
stronger	confinement	effect.	DOS	-	electronic	density	of	states.	(Figure	redrawn	after	ref.	[11]).	
Doing the math on what has just been outlined about graphene and 
especially GO, several appealing features appear to project these materials 
toward powerful biotechnological applications. However, in order to draw fully 
from graphene/GO it is imperative to exhaustively reveal their chemistry and 
physics as well as their interaction with biology. On the other hand, this lack of 
knowledge leaves some room for yet unexploited research areas. 
In light of the above, here we started to explore some of the GO potential 
for drug delivery. In particular, based on a robust platform for the preparation 
of LbL lipid NCs, we tried to add GO nanosheets on our delivery systems. To 
this aim, very little has been done for the integration of GO nanosheets with 
nanosized drug delivery systems. To the best of our knowledge, the only 
relevant cases deal with the LbL deposition of GO on sacrificial template 
microcapsules [30-32]. Thus, the first real objective of this work was coating 
nanosized liquid templates with GO. This step required manipulation and 
following analysis of the commercially available GO in order to allow for its 
LbL deposition on our NEs. The GO multilayer NCs were characterized by 
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DLS and cryo-TEM. Moreover, they showed strong fluorescent emission in the 
visible region of light under two-photon excitation.  
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4.2	Results	and	Discussion	
Graphene	 oxide	 modification	 and	 its	 deposition	 on	
O/W	nanoemulsions		
When we tried to deposit a suspension of these GO sheets on our NEs, the 
LbL process did lead to a complete aggregation of the system. Thereby, we first 
tried to get insight on the size distribution of the GO suspension. The cryo-
TEM image in Figure 4.2.1 reveals the average dimensions of the commercial 
GO, as it was supplied from the manufacturing company. Based on the 
experience matured on our system, an increase in GO Z-potential (absolute 
value) and a reduction of the sheets size were auspicated to achieve the LbL 
deposition of a GO layer around the nanosized liquid templates.  
 
 
Figure	 4.2.1	 Cryo-TEM	 image	 of	 GO	 as	 supplied	 from	 the	 company	 manufacturer	 (Sigma	 Aldrich).	
(Scale	bar	100	nm).	
Following this aim, we chemically treated the commercial GO converting the 
oxydril groups into carboxylic acids as highlighted by the X-rays photoelectron 
spectroscopy (XPS) analysis. Figure 4.2.1 shows the high resolution C1s XPS 
spectra for pristine GO (a) and treated GO (b). Six components have been 
fitted for each sample with Gaussian peaks centered at 284.7, 284.88, 286.78, 
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287.49, 288.60 and 290.53 eV corresponding to C=C, C-C, C-O, C=O, COOH 
and 𝜋 – 𝜋∗ . Minor (0.1 – 0.5 eV) shift/error in the binding energies were 
detected between the pristine and treated spectra. The contribution of each 
individual functional group is shown in the figure legends. Comparing the two 
samples it is clear how the C-O contribution dramatically decreases in treated 
GO, while the COOH increases. These results confirmed that the chemical 
treatment with chloroacetic acid effectively determined a certain degree of 
carboxylation of GO. At the same time, the treated GO XPS spectrum also 
showed an increase of C=C contribution which may be indicative of a partial 
restoration of sp2 domains. These results combined with the UV spectra in 
Figure 4.2.2 suggest that the increase in the concentration of sp2 hybridized 
carbon atoms partially restored a graphene-like nature. The red shift of main 
absorption peak of treated GO to 265 nm and the increase of absorption in the 
whole spectral region indicate that 𝜋 – 𝜋∗ transitions of C=C are dominant on 𝑛 – 𝜋∗of the C=O. These results are consistent with the typical UV spectra 
obtained after weak reduction process as reported in ref. [32]. 
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Figure	4.2.2	C1s	XPS	spectra	for	pristine	GO	(a)	and	treated	GO	(b).	
To explain this combined effect of partial oxidation of GO on one side, and 
a certain degree of reduction to sp2 carbon atoms on the other side, we 
formulated the following hypothesis: the chemical treatment of GO with 
chloroacetic acid was responsible for a partial oxidation of C-OH to –COOH 
groups. At the same time, the sonication of GO under alkaline conditions and 
slight increasing temperature - due to dissipation of energy - led to an increase 
of sp2 domains. In particular, the higher concentration of C=C groups 
apparently might be attributed to partial removing of carbonaceous oxidation 
debris from GO [33]. This low molecular weight fraction, made of a bunch of 
oxidative polyaromatic fragments, has been found to strongly adsorbed on GO 
by non-covalent interactions acting as a lubricant among the sheets [33, 34]. 
a	
b	
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Therefore, in spite of a proper reduction process, which for GO is generally 
reported to take place under strong alkaline conditions (as in case of hydrazine 
reduction [35]), here we assume that the increase of the C=C contribution 
actually depends on the proportional decrease of the C=O components after 
base-washing during the sonication process. 
It is noteworthy that a good compromise between the oxidized and reduced 
GO form is crucial in order to preserve water dispersion ability and the non-
zero energy band gap.  
 
 
Figure	4.2.3	UV-visible	spectra	of	GO	before	and	after	chemical/thermo-mechanical	treatment.	
The size decrease of GO sheets after treatment is pretty evident from Figure 
4.2.4 comparing the cryo-TEM images of GO before (Fig. 4.2.4a) and after 
sonication (Fig. 4.2.4b). 
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Figure	4.2.4	Cryo	TEM	images	of	GO	before	(a)	and	after	(b)	sonication.	(Scale	bar:	100nm). 
The as prepared GO was then assembled around 2% v/v O/W NEs thanks 
to a LbL procedure allowing for a high control over the deposition process, as 
already described elsewhere (see chapters 2 and 3 and ref [36]). Due to the 
nanoscale size of the templates and to their liquid state, performing the LbL of 
GO nanosheets was not straightforward. The same applies for morphology, 
although from cryo-TEM images in Figure 4.2.5 (b,d) the formation of GO 
coating around the NE template is pretty evident. Following this procedure, we 
deposited on NEs two layers of negatively charged GO alternated to positively 
charged chitosan. We monitored the evolution of the NCs from the starting NE 
until the formation of a tetralayer by DLS and the average values of size PDI 
and Z-potential are summarized in Figure 4.2.5.  
 
a	 b	
 97 
 
Figure	4.2.5	Characterization	of	GO	multilayer	NCs	during	LbL	deposition	process	by	(a)	DLS,	(b)	and	
(d)	cryo-TEM,	(c)	Z-potential.	(Scale	bar:	100	nm).	
The GO tetralayer NCs were also observed at the multi-photon confocal 
microscope. When excited between 700 and 960 nm they showed an intense 
fluorescence emission over the visible region of wavelengths (Figure 4.2.6b). 
Usually, photosensitizers absorb light in the visible spectral region below 700 
nm, where light penetration into the tissue is limited and one-photon absorption 
induced auto-fluorescence is higher. Whereas, the 700–900 nm wavelength 
range is typically recognized as a main optical transparent window for tissues, as 
Rayleigh scattering is very low. Therefore, two-photon luminescence 
microscopy making use of NIR femtosecond excitation source is highly 
demanded for bioimaging applications.  
Although GO fluorescence has been already described and debated, there are 
only few example reporting two-photon induced emission. Encouraged by the 
non-trivial optical response of our system we further investigated GO NCs 
luminescence by in vitro live imaging. After 24 h of incubation with both human 
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primary glioblastoma (U87) and primary human dermal fibroblasts (HDF) cells, 
GO NCs were taken up and showed intense fluorescence signal (Figure 4.2.7). 
No significant changes were observed when the wavelength was varied between 
780 nm and 900 nm even at the very low laser power. It is noteworthy that a 
two-photon molecular dye exhibiting a photoluminescence that can be excited 
with a wider range of wavelengths is itself of practical significance in 
bioimaging. These preliminary results allowed for highly cyto-compatible 
imaging conditions paving the way to a new set of in vitro experiments. 
 
 
Figure	4.2.6	Multi-photon	microscope	images	of	GO	NCs	in	bright	field	(a),	fluorescence	(b),	and	their	
overlay	(c).	(Scale	bar:	10	µm).	
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Figure	4.2.7	Multiphoton	confocal	microscope	images	of	tetralayer	GO/CT	NCs	after	internalization	in	
both	U87	and	HDF	cells.	a,	b:	bright	field	images;	c,	d:	multiphoton	fluorescence	images;	e,	f:	overlay	
of	bright	field	and	multiphoton	fluorescence	images.	(Scale	bar:	40	µm).	
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4.3	Conclusions	
The main ambition of this work was trying to assemble few atoms-thick GO 
sheets on oil-core NCs in order to develop an innovative drug delivery platform. 
Although GO deserves deeper understanding as a material itself, it has already 
disclosed part of its great potential in the biomedical field. Among the many 
remarkable feature of GO, drug delivery would particularly benefit from the 
unparalleled loading capacity of hydrophobic molecules, the multi-photon 
induced luminescence and the ability to transduce NIR light into heat. So far the 
only examples where GO has been integrated into drug delivery systems 
involves the use of microcapsules and stand-alone GO. Encouraged by the non 
conventional opportunities GO promises to offer, we successfully built GO 
multilayer NCs combining an effective chemical/structural modification of the 
material with a robust technique for the preparation of oil-core multilayer NCs. 
To confirm the quality of the system we provided spectroscopic, dimensional 
and morphological evidences. Moreover, the GO NCs showed a powerful two-
photon fluorescence that incentivized further study for bioimaging applications. 
Preliminary in vitro imaging experiments highlighted a massive uptake by two 
different cell lines through the intense fluorescence of GO NCs over a broad 
band of wavelengths. These results unfold some interesting scenarios including 
the chance to track the fate of the drug delivery system after its administration.  
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4.4	Future	Perspectives	
Based on the photo-thermal properties reported on GO, we are 
currently exploring the ability of GO NCs to transduce the NIR light 
into heat. This prerogative could enable our system for a double 
therapeutic approach. The heat generated under biocompatible 
wavelengths, indeed, might both induce tumor cell death by 
hyperthermia and trigger the release of an anticancer drug from the 
NCs. By coupling these two effects, indeed, one could benefit from the 
photo-thermal therapeutic approach on the short time scale, while the 
stimuli responsive drug delivery system may exert its action on a longer 
time scale. 
As a future prospective we will thus devote some efforts to further 
study GO optical properties with the ambition of combining its 
intriguing features into a graphene-based multimodal therapeutic 
platform of real interest for nanomedicine. 
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4.5	Materials	and	Methods	
Materials	
O/W NEs were prepared using Soybean oil (density of 0.922 g/ml 
at 20 °C) and surfactant Lipoid E80 (egg lecithin powder 80-85% 
enriched with Phosphatidyl choline (PC) and 7-9.5% content in 
phosphatidyl ethanolamine (PE)) purchased from Lipoid and used 
without further purification. Millipore® Milli-Q water was used for the 
preparation of all NEs and solutions. Chloroacetic acid (ClCH2COOH 
m.w. = 94.5 g/mol), Sodium hydroxide (NaOH m.w. = 40.0 g/mol), 
(CT, LMW 90-150 kDa, DDA 84% determined via 1H-NMR) and 
graphene oxide water suspension (GO 2 mg/ml) were purchased from 
Sigma Aldrich.  
 
Oil-in-Water	nanoemulsion		
The O/W NE was prepared as previously described (see chapter 2). 
Briefly, the oil phase was prepared by adding an exact amount of Lipoid 
E 80 to the soy-bean oil at 60 °C and then sonicated with an immersion 
sonicator (Ultrasonic Processor VCX500 Sonic and Materials). To 
obtain the pre-emulsion, the oil phase was added dropwise to a 
weighted amount of aqueous phase (Milli-Q water) and mixed using the 
immersion sonicator. The pre-emulsion was finally passed at 2000 bar 
through the high-pressure valve homogenizer (Microfluidics M110PS) 
to obtain the final NE.  
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Chemical	 and	 structural	 modification	 of	
graphene	oxide		
Commercial GO was chemically modified based on a procedure 
described elsewhere [22]. In order to convert -OH groups into -COOH, 
10 ml of graphene oxide water suspension (GO 2 mg/ml) was diluted 
to 0.05 mg/ml with Milli-Q water and sonicated for one hour. Then, 30 
mg of NaOH plus 25 mg of ClCH2COOH were added to the 
suspension and bath sonicated for other 2 hours. The suspension was 
also thermo-mechanically treated with an immersion sonicator for an 
extra hour. Afterwards, the reaction mixture was neutralized with HCl 
and washed several times with Milli-Q. The carboxylated GO was 
finally freeze-dried and stored in dry conditions ready to use. 
 
LbL	 deposition	 of	 modified	 graphene	 oxide	 on	
O/W	nanoemulsions		
Monolayer, bilayer, trilayer and tetralayer were obtained with a 
customized LbL deposition procedure [36] already reported in chapter 2 
and 3. Briefly, the tetralayer NCs were prepared by aid of two syringe 
pumps (HARVARD APPARATUS 11 PLUS) and an ultrasonic bath 
(FALC INSTRUMENTS). Starting from the chitosan coated NE (1 
wt% oil and 0.01 wt% chitosan), a negatively charged second GO layer 
was deposited by mixing 1 : 1 (v : v) of a 0.1 wt% aqueous solution of 
GO with the NE suspension. The same procedure was repeated also for 
the deposition of the subsequent chitosan and GO layers leading to the 
following final concentrations: 0.0125 % (w/v) O/W NE, 0.002 % 
(w/v) CT, 0.0263 % (w/v) GO.  
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Particle	size	and	Z-potential	measurements		
The setting parameters for both Particle size and Z-potential 
measurements were the same as described in chapter 2. All the 
suspensions were diluted to a droplet concentration of approximately 
0.025 (wt%), using Milli-Q water in the case of nano-emulsion and 
multilayers terminating with GO, while the NCs terminating with a 
chitosan layer were diluted in acidified Milli-Q water solution (pH 4).  
 
XPS	analysis		
XPS spectra were recorded using a PHI5000VersaProbeII XPS 
spectrometer with a monochromatic Al-K-α source of 1486.68 eV. The 
high resolution C1s spectra were acquired at high power (100 W) with a 
Pass Energy of 23.5 eV, 0.1 eV step size, and averaged over 20 scans. 
Spectra from insulating samples were charged corrected by shifting all 
peaks to the adventitious carbon C1s spectral component binding 
energy set at 284.8 eV. Multipack software was used to process all the 
spectra. 
 
Cryo-TEM	analysis	
The morphology of the NEs and multilayer NCs were observed by 
cryo-TEM. In particular, frozen hydrated samples were prepared by 
applying a 3 µl aliquot to a previously glow-discharged 200 mesh holey 
carbon grid (Ted Pella, USA). Before plunging into nitrogen cooled 
liquid ethane, the grid was blotted for 1.5 s in a chamber at 4 °C and 
90% humidity using a FEI Vitrobot Mark IV (FEI company, the 
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Netherlands). The particles were imaged using a Tecnai G2 F20 
transmission electron microscope (FEI company, the Netherland) 
equipped with a Shotky field emission gun operating at an acceleration 
voltage of 200 kV and recorded at low dose with a 2k x 2k Ultrascan 
(Gatan, USA) CCD camera. 
 
Cell	culture	and	sample	preparation	
To test the biological effect of GO NCs, human glioma cell line 
(U87-MG), and primary human dermal fibroblasts (HDF) were used as 
models of tumor and healthy tissues respectively.  
HDF cells were cultured in Eagle’s minimal essential medium 
(EMEM) supplemented with 20% Bovine Serum Albumine (FBS, 
Gibco), 100 U/mL penicillin, and 100 mg/ml streptomycin and 2X 
non-essential aminoacids. U87-MG cells were cultured with EMEM 
supplemented with 10% FBS and antibiotics.  
Both cell lines were maintained in 100 mm diameter cell culture in a 
humidified controlled atmosphere with 95% to 5% ratio of air/CO2, at 
37 °C. The medium was changed every 2–3 days. 
For Imaging experiments, 4x104 HDF and U87 cells were seeded in 
35mm glass bottom dishes (WillCo-Wells) and incubated for 24 h in a 
humidified atmosphere at 37 °C and 5% CO2 to obtain a subconfluent 
monolayer. After that, cells were incubated for 24 h with GO NCs. 
Then, samples were washed twice with PBS to remove non internalized 
NPs and cell medium was added.  
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	GO	nanocapsules	imaging	in	living	cells		
Samples were observed by LSM microscope system (Leica TCS SP5 
II) equipped with multiphoton module based on a Ti sapphire NIR 
coherent laser (Chamaleon ultra II). A water-immersion 40x/1.1 
objective was used to acquire images of living cells, using 800 nm as 
excitation wavelength at very low laser power. Images were acquired 
with a resolution of 1024x1024 pixels. 
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Chapter	5	
Conclusions	
In the recent years the huge wave of progress in science at the nanoscale has 
blossomed a new field of technologies applied to healthcare broadly named 
nanomedicine. In principle, the manipulation of materials at the nanometer level 
and the different properties that arise from there not only could overcome the 
limitations of the conventional therapeutic approaches but also revolutionize 
our idea of medicine. One of the main themes in nanomedicine is improving the 
efficacy of traditional therapeutic agents, especially in the treatment of cancer. 
To this purpose, the mainstream strategy is based on the design of delivery 
systems capable of positively affect the pharmacokinetic and biodistribution of 
drugs after their administration while reducing unpleasant side effects. In order 
to meet these fundamental requirements an ideal delivery system should first of 
all improve the solubility of the drugs where the most relevant therapeutics, 
especially anticancer agents, are highly hydrophobic molecules. At the same time 
it is crucial keeping the size of the delivery system small enough to minimize its 
clearance from the body and to exploit the ability of ≈ 100 nm particles to 
extravasate and enter the diseased tissue or the tumor. Even this relatively easy 
task is not obvious to carry out. In fact, delivery systems with a good 
compromise between dimensional features and a meaningful loading capacity 
have not been reported yet as a consolidated achievement by the literature. It is 
in this direction that the first efforts of this research work were devoted. Indeed, 
we developed a robust platform for the preparation of monodisperse oil-core 
nanocapsules capable of dissolving large amounts of hydrophobic drugs. Liquid 
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templates could virtually represent a viable way for the encapsulation of actives 
of importance for drug delivery. For this reason we strived to overcome some 
important issues in handling the high reactivity of these promising nanocapsular 
systems. In particular, an extremely versatile method for the electrostatic 
deposition of charged molecules at the interface of liquid nanocapsules has been 
developed. Starting from ultrastable secondary nanoemulsions, this technique 
allowed for the engineering of multifunctional polymeric nanocapsules made up 
of a number of diverse materials including: nature-derived polyelectrolytes, 
polysaccharides conjugated with peptides and graphene oxide nanosheets. We 
believe that the results reported in this work could actually contribute to boost 
the use of nanocapsules based on liquid templates as a useful tool for effective 
drug delivery.  
As already mentioned, beyond the solubility issue there are other 
fundamental requirements to meet for improving the efficacy of conventional 
therapies. However, to date these higher purposes still remain challenging tasks. 
Too little is known to establish a priori if a strategy is better than another one. 
Ultimately, the processes underlying the interactions between the delivery 
system and the physiological environment are more sophisticated than what we 
can still predict. Hence, any study aimed at improving drug pharmacokinetics 
and minimizing its side effects is useful for the literature. In this work we tried 
to address these issues following two different approaches. In chapter 3 we 
presented a strategy to enhance the stability of nanocapsules and allow for a 
spatially controlled release mechanism. Basically, to reduce off-target toxicity 
and improve the performance of the drug it is crucial both preventing the 
systemic leakage of the drug and enabling the nanocapsules to release their 
payload only when they reach the target site could actually. The strategy we 
propose makes use of a single tool to address both the stability and the specific 
release issue. The central element is a Matrix Metalloproteases-2 responsive 
peptide that we embedded in our nanocapsules. Through a click chemistry 
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conjugation the peptide allowed to extend the nanocapsule stability in 
physiological media up to one month. Moreover, we tried to achieve a tumor 
selective release of the drug by a stimuli-responsive approach. Among the 
possible stimuli we chose the catalytic activity of these enzymes, which are 
typically overexpressed in tumor microenvironments. Preliminary results seem 
to encourage the use of a endogenous cues to trigger an on demand release. 
However, further biological studies are needed to validate the system. 
 A stimuli-responsive approach was also followed in the last part of this work 
where we presented an early study on the use of graphene oxide as a powerful 
tool for biomedical applications. The interest for this innovative material is 
rapidly increasing due to some intriguing properties including its intense optical 
adsorption in the near-infrared region of wavelengths. However, to date very 
little has been done for the integration of graphene oxide into nanosized drug 
delivery systems. In this context, we successfully coated oil-core nanocapsules 
with graphene oxide nanosheets and chitosan. The nanocapsules showed 
interesting optical properties including an intense near-infrared induced 
fluorescence which can be of real interest for biotechnology applications. 
Moreover, we are currently exploring the potential of graphene oxide to 
transduce light into thermal energy to trigger the release of chemotherapeutic 
agents from the nanocapsules in a remote control fashion.   
Taken altogether the results of this work of thesis encourage the use of oil-
core nanocapsules as a viable tool for addressing the solubility issue of most 
therapeutics and implementing more sophisticated drug delivery systems of 
interest for nanomedicine.  	
  	
